var title_f12_44_12992="Placenta and membranes in twin pregnancies";
var content_f12_44_12992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Placenta and membranes in twin pregnancies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Two placentas, two amnions, two chorions (from either dizygotic twins or monozygotic twins with cleavage of zygote during first 3 days after fertilization). (B) One placenta, one chorion, two amnions (monozygotic twins with cleavage of zygote from the fourth to the eighth day after fertilization). (C) One placenta, one chorion, one amnion (monozygotic twins with cleavage of zygote from the eighth to the twelfth day after fertilization).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_12992=[""].join("\n");
var outline_f12_44_12992=null;
var title_f12_44_12993="Teicoplanin: International drug information";
var content_f12_44_12993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Teicoplanin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1980202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Targocid (AR, AT, AU, BE, BR, CH, CZ, DE, DK, ES, FI, FR, HR, HU, IE, LU, MX, NL, NO, SE);",
"     </li>",
"     <li>",
"      Targosid (IT, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections caused by susceptible gram-positive bacteria; prophylaxis against gram-positive endocarditis in dental surgery; peritonitis associated with CAPD",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 10 mg/kg I.V. every 12 hours for 3 doses, then 6 mg/kg I.V. or I.M. once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For more severe infections: 10 mg/kg I.V. every 12 hours for 3 doses, followed by 10 mg/kg I.V. or I.M. once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 6 mg/kg (&sim;400 mg) on the first day, followed by 3 mg/kg (&sim;200 mg) once daily thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     For more severe infections: 6 mg/kg (&sim;400 mg) given every 12 hours for 3 doses, followed by 6 mg/kg/day; doses up to 12 mg/kg/day may be used",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: 200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10435 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_12993=[""].join("\n");
var outline_f12_44_12993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980202\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980197\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980200\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980196\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821087\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980199\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10435|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_44_12994="Colostomy irritant contact";
var content_f12_44_12994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irritant contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exposure to damaging effluent can produce severe skin breakdown in the area exposed to the drainage; this type of skin damage is characterized by severely denuded skin along the inferior aspect of the stoma and is most common among ileostomy patients and patients with problematic stomas (eg, stomas that are retracted and empty below skin level).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy B Doughty, MN, RN, CWOCN, FAAN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_12994=[""].join("\n");
var outline_f12_44_12994=null;
var title_f12_44_12995="DIF of linear IgA bullous dermatosis";
var content_f12_44_12995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence microscopy of linear IgA bullous dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A linear band of fluorescence representing deposition of IgA along the basement membrane zone is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_12995=[""].join("\n");
var outline_f12_44_12995=null;
var title_f12_44_12996="Finasteride: Patient drug information";
var content_f12_44_12996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Finasteride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     see \"Finasteride: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Propecia&reg;;",
"     </li>",
"     <li>",
"      Proscar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Finasteride;",
"     </li>",
"     <li>",
"      CO Finasteride;",
"     </li>",
"     <li>",
"      JAMP-Finasteride;",
"     </li>",
"     <li>",
"      Mint-Finasteride;",
"     </li>",
"     <li>",
"      Mylan-Finasteride;",
"     </li>",
"     <li>",
"      PMS-Finasteride;",
"     </li>",
"     <li>",
"      Propecia&reg;;",
"     </li>",
"     <li>",
"      Proscar&reg;;",
"     </li>",
"     <li>",
"      ratio-Finasteride;",
"     </li>",
"     <li>",
"      Sandoz-Finasteride;",
"     </li>",
"     <li>",
"      Teva-Finasteride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help hair growth in male pattern baldness. It may take 3 months to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692109",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat the signs of an enlarged prostate. It may take a few months to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2861222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop prostate cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702125",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to finasteride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not donate blood while using this drug and for 1 month after stopping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If taking for an enlarged prostate, have a rectal exam (to check prostate gland) and blood work (PSA test). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant, do not handle crushed or broken tablets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3473515",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast growing prostate cancer may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2861223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast, breast soreness, or nipple discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12473 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_12996=[""].join("\n");
var outline_f12_44_12996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171302\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171303\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019741\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019740\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019745\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019746\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019748\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019743\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019744\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019749\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019750\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=related_link\">",
"      Finasteride: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_44_12997="Aphthous ulcer";
var content_f12_44_12997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56488%7EDERM%2F63475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56488%7EDERM%2F63475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aphthous ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD, Duke Pediatric Dentistry.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aphthous ulcers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Round, yellow-gray ulcers are present on the oral mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_12997=[""].join("\n");
var outline_f12_44_12997=null;
var title_f12_44_12998="Deep vein thrombosis (DVT)";
var content_f12_44_12998=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/44/12998/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12998/contributors\" id=\"au8781\">",
"       Menaka Pai, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12998/contributors\" id=\"au8652\">",
"       James D Douketis, MD, FRCPC, FACP, FCCP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/44/12998/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12998/contributors\" id=\"se1211\">",
"       Lawrence LK Leung, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/44/12998/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12998/contributors\" id=\"de8916\">",
"       Geraldine Finlay, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?12/44/12998?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DEEP VEIN THROMBOSIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Venous thrombosis is a condition in which a blood clot (thrombus) forms in a vein. This clot can limit blood flow through the vein, causing swelling and pain. Most commonly, venous thrombosis occurs in the \"deep veins\" in the legs, thighs, or pelvis (",
"     <a class=\"graphic graphic_figure graphicRef70603 \" href=\"UTD.htm?24/47/25343\">",
"      figure 1",
"     </a>",
"     ); this is called a deep vein thrombosis, or DVT.",
"    </p>",
"    <p>",
"     Venous thrombosis can form anywhere in the venous system. However, DVT is the most common type of venous thrombosis. If a part or all of the blood clot in the vein breaks off from the site where it is formed, it can travel through the venous system; this is called an embolus. If the embolus lodges in the lung, it is called pulmonary embolism (PE), a serious condition that leads to over 50,000 deaths a year in the United States. In most cases, PE is caused by a DVT when part of a blood clot breaks off and lodges in the lung. The term \"venous thromboembolism\" is sometimes used when discussing both DVT and PE.",
"    </p>",
"    <p>",
"     This topic review discusses the risk factors, signs and symptoms, diagnostic process, and treatment of a deep vein thrombosis. The diagnosis and treatment of pulmonary embolisms are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"      \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DEEP VEIN THROMBOSIS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of factors that increase a person's risk of developing a deep vein thrombosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Inherited thrombophilia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inherited thrombophilia refers to a genetic problem that causes the blood to clot more easily than normal. Various factors in the blood clotting process may be involved, depending on the type of genetic problem present.",
"    </p>",
"    <p>",
"     An inherited thrombophilia is frequently present in people with a venous blood clot (ie, thrombus). For example, deficiencies of antithrombin, protein C, or protein S can be found in approximately 5 percent of patients who have had a venous blood clot and are less than 50 years of age. Other factors, such as factor V Leiden or the prothrombin gene mutation, are found in up to 5 percent of otherwise healthy Caucasians and can occur in approximately 20 to 25 percent of people with a venous blood clot. Venous thrombosis is infrequent before adolescence in people with inherited thrombophilia.",
"    </p>",
"    <p>",
"     If a person is found to have a DVT and there is no known medical condition or recent surgery that could have caused the DVT, it is possible that an inherited condition is the cause. This is especially true in people with a family member who has also experienced a DVT or pulmonary embolism. In these cases, testing for an inherited thrombophilia may be recommended (see",
"     <a class=\"local\" href=\"#H16\">",
"      'Finding the cause of venous thrombosis'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Elevated clotting factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having an increased level of one or more factors involved in blood clotting, such as factor VIII, increases the risk of a blood clot.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Medical conditions or medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some medical conditions and medications increase a person's risk of developing a blood clot:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pregnancy",
"      </li>",
"      <li>",
"       Obesity",
"      </li>",
"      <li>",
"       Smoking",
"      </li>",
"      <li>",
"       Heart failure",
"      </li>",
"      <li>",
"       Previous DVT or PE",
"      </li>",
"      <li>",
"       Increased age",
"      </li>",
"      <li>",
"       Cancer &mdash; Some cancers increase substances in the blood that cause blood to clot.",
"      </li>",
"      <li>",
"       Kidney problems, such as nephrotic syndrome (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=see_link\">",
"        \"Patient information: The nephrotic syndrome (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Certain medications (eg, birth control pills, hormone replacement therapy, erythropoietin, tamoxifen, thalidomide). The risk of a blood clot is further increased in people who use one of these medications, and also smoke or are obese.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Surgery and related conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgical procedures, especially those involving the hip, pelvis, or knee, increase a person's risk of developing a blood clot. During the recovery period, this risk often continues because the person is less active. Inactivity during long trips can also increase a person's risk of developing a blood clot. Precautions to reduce the risk of blood clots are discussed below (see",
"     <a class=\"local\" href=\"#H23\">",
"      'Deep vein thrombosis prevention'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Major surgery (especially orthopedic surgery and neurosurgery)",
"      </li>",
"      <li>",
"       Trauma, especially if blood vessels are injured",
"      </li>",
"      <li>",
"       Prolonged sitting, especially sitting for six or more hours on a plane, or bed rest",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Acquired thrombophilia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some types of thrombophilia are not inherited, but can increase a person's risk of developing a blood clot.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Certain disorders of the blood, such as polycythemia vera or essential thrombocythemia",
"      </li>",
"      <li>",
"       Antiphospholipid antibodies (antibodies in the blood that can affect the clotting process) (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"        \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      DEEP VEIN THROMBOSIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The signs and symptoms of DVT may be caused by the clot, or may be related to another condition. Imaging studies are needed to determine if a clot is present.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Deep vein thrombosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Classic symptoms of DVT include swelling, pain, warmth, and redness in the involved leg.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Superficial phlebitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Superficial phlebitis (SP) causes pain, tenderness, firmness,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     redness in a vein due to inflammation, infection,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a blood clot (thrombus). It is most commonly seen in the inner part of the lower legs.",
"    </p>",
"    <p>",
"     Superficial phlebitis differs from a deep vein thrombosis because the veins that are affected are near the surface of the skin. Symptoms of SP typically develop over hours to days and resolve in days to weeks. The area may continue to be firm for several weeks to months. Treatment usually includes warm or cool compresses, elevation of the leg, and a non-steroidal antiinflammatory agent (NSAID), such as ibuprofen (Advil, Motrin). In most people with SP, there is a low risk of developing a pulmonary embolism, so anticoagulation is not usually needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      DEEP VEIN THROMBOSIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If the patient's history, symptoms, and physical exam suggest a DVT, tests are needed to confirm this. Tests to diagnose DVT may include compression ultrasonography, contrast venography, magnetic resonance imaging (MRI), computed tomography (CT scan),",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a blood test called D-dimer.",
"    </p>",
"    <p>",
"     If a person with a DVT also has signs or symptoms of a pulmonary embolus, additional testing will be needed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"      \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      D-dimer",
"     </span>",
"     &nbsp;&mdash;&nbsp;D-dimer is a substance in the blood that is often increased in people with DVT or PE. D-dimer testing is employed for patients with suspected DVT or PE. If the D-dimer test is negative and the patient has a low risk of DVT or PE based upon",
"     <span class=\"nowrap\">",
"      his/her",
"     </span>",
"     history and physical examination, DVT or PE are unlikely and further diagnostic testing may not be needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Compression ultrasonography",
"     </span>",
"     &nbsp;&mdash;&nbsp;Compression ultrasonography uses sound waves to generate pictures of the structures inside the leg. For this type of exam, a person lies on",
"     <span class=\"nowrap\">",
"      his/her",
"     </span>",
"     back and then stomach as an ultrasound wand is applied to the leg. In most circumstances, compression ultrasonography is the test of choice for patients with suspected DVT.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Contrast venography",
"     </span>",
"     &nbsp;&mdash;&nbsp;During contrast venography, a catheter is threaded into a vein and a dye is injected. This allows the clinician to see the vein with x-ray. Venography is generally reserved for situations in which ultrasound cannot be done, when other tests have not been helpful, or when other tests are negative but the clinician feels strongly that a venous thrombosis is present.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Magnetic resonance imaging (MRI)",
"     </span>",
"     &nbsp;&mdash;&nbsp;MRI uses a strong magnet to produce detailed pictures of the inside of the body. MRI is as accurate as contrast venography. MRI is expensive, and its use may be limited to situations in which contrast venography cannot be performed, such as in patients with poor kidney function, during pregnancy, or because of allergy to the dye required in contrast venography.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Finding the cause of venous thrombosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;After determining that DVT or PE is present, the healthcare provider will want to know what caused it. In many cases, there are obvious risk factors such as recent surgery or immobility. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Acquired thrombophilia'",
"     </a>",
"     above.) In other cases, the clinician may test for the presence of an inherited form of thrombophilia or for another medical condition associated with an increased risk for venous thrombosis. (See",
"     <a class=\"local\" href=\"#H3\">",
"      'Inherited thrombophilia'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Persons with an acquired or inherited abnormality may require additional treatment or prevention measures to reduce the risk of another thrombosis. Some experts recommend that the family members of a person with an inherited thrombophilia be screened for the inherited condition if this information would affect the patient&rsquo;s care, although this issue is controversial. It is important that the healthcare provider discusses the pros and cons of screening for an inherited thrombophilia with the patient before this testing is done.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      DEEP VEIN THROMBOSIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of DVT and PE is similar. In DVT, the main goal of treatment is to prevent a PE. Other goals of treatment include preventing the clot from becoming larger, preventing new blood clots from forming, and preventing long-term complications of PE or DVT.",
"    </p>",
"    <p>",
"     The primary treatment for venous thrombosis is anticoagulation. Other available treatments, which may be used in specific situations, include thrombolytic therapy or placing a filter in a major blood vessel (the inferior vena cava).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Anticoagulation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulants are medications that are commonly called \"blood thinners\". The medication does not actually thin the blood, but rather helps to prevent new blood clots from forming. Patients with venous thrombosis are usually treated first with an injectable anticoagulant. There are several such anticoagulants available, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Unfractionated heparin, often given into a vein (intravenous)",
"      </li>",
"      <li>",
"       Low molecular weight heparin",
"       <span class=\"nowrap\">",
"        (enoxaparin/Lovenox,",
"       </span>",
"       <span class=\"nowrap\">",
"        dalteparin/Fragmin,",
"       </span>",
"       or",
"       <span class=\"nowrap\">",
"        tinzaparin/Innohep)",
"       </span>",
"      </li>",
"      <li>",
"       Fondaparinux (Arixtra)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These agents can all be injected under the skin (ie, subcutaneous injection) by the patient, a family member, or a home health nurse. This allows selected patients to be treated at home. Heparin, low molecular weight heparin, or fondaparinux are usually continued for at least five days, along with another medication called warfarin (Coumadin). Warfarin is a pill that is taken by mouth. After approximately five days, the heparin, low molecular weight heparin or fondaparinux are discontinued while the warfarin is continued for at least three months.",
"    </p>",
"    <p>",
"     Other treatment options include rivaroxaban (Xarelto), which is a pill that is taken by mouth, and does not require an overlap with an injectable anticoagulant. Less commonly, the patient does not take warfarin or rivaroxaban but takes a daily injection of low molecular weight heparin or fondaparinux for the entire treatment period. Low molecular weight heparin, fondaparinux, and rivaroxaban are more expensive than warfarin, but they do not need to be monitored with blood clotting tests.",
"    </p>",
"    <p>",
"     For patients taking warfarin, the clotting factors in the blood need to be measured on a regular basis with a blood test called the International Normalized Ratio (INR). The target level INR for people on warfarin is usually between 2 and 3. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The choice of anticoagulant usually depends upon the healthcare provider's preference, the patient's medical condition, and cost issues.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Duration of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Warfarin (Coumadin) is recommended for a",
"     <strong>",
"      MINIMUM",
"     </strong>",
"     of three months in a patient with DVT.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In patients who had a reversible risk factor contributing to their DVT, such as trauma, surgery, cancer, or being confined to bed for a prolonged period, the person is often treated with anticoagulation for three months or until the risk factor is resolved.",
"      </li>",
"      <li>",
"       Expert groups recommend that people who develop a venous thrombosis and who do not have a known risk factor for thrombosis be treated with an anticoagulant for an indefinite period of time [",
"       <a class=\"abstract\" href=\"UTD.htm?12/44/12998/abstract/1\">",
"        1",
"       </a>",
"       ]. However, this decision should be discussed with the person's healthcare provider after three months of treatment, and then reassessed on a regular basis. Some people prefer to continue the anticoagulant, which may carry an increased risk of bleeding, while others prefer to stop the anticoagulant at some point, which may carry an increased risk for repeat thrombosis.",
"      </li>",
"      <li>",
"       People who have an underlying medical risk factor for thrombosis, such as the antiphospholipid syndrome, are advised to continue anticoagulation indefinitely after a first spontaneous DVT or PE.",
"      </li>",
"      <li>",
"       Most experts recommend continuing anticoagulation indefinitely for people with two or more episodes of venous thrombosis or if a permanent risk factor is present (eg, a mechanical heart valve).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Walking during DVT treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Once an anticoagulant has been started and symptoms (eg, pain, swelling) are under control, the person is strongly encouraged to get up and walk around. Studies show that there is no increased risk of complications (eg, pulmonary embolus) in people who get up and walk, and walking may help the person feel better faster.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Thrombolytic therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some cases, a healthcare provider will recommend an intravenous medicine to dissolve blood clots. This is called thrombolytic therapy. This therapy is more likely to be used in patients who have serious complications related to PE or DVT, and who have a low risk of serious bleeding as a side effect of the therapy. The response to thrombolytic therapy is best when there is a short time between the diagnosis of",
"     <span class=\"nowrap\">",
"      DVT/PE",
"     </span>",
"     and the start of thrombolytic therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Inferior vena cava filter",
"     </span>",
"     &nbsp;&mdash;&nbsp;An inferior vena cava (IVC) filter is a device that blocks the circulation of clots in the bloodstream. It is placed in the inferior vena cava (the large vein leading from the lower body to the heart). The IVC filter typically is inserted through a small incision in a neck vein with the use of a local anesthetic and takes 20 to 30 minutes to perform. An IVC filter is often recommended in patients with venous thromboembolism who cannot use anticoagulants because of a very high bleeding risk.",
"    </p>",
"    <p>",
"     Use of an IVC filter may be recommended in patients who develop recurrent thromboembolism despite anticoagulation, and in patients with pulmonary problems due to chronic recurrent embolism, although this is controversial. In the long term, IVC filters can increase the risk of developing blood clots.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      DEEP VEIN THROMBOSIS PREVENTION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Surgical patients",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain high risk patients undergoing surgery (especially bone or joint surgery and cancer surgery) may be given anticoagulants to decrease the risk of blood clots. Anticoagulants may also be given to women at high risk for venous thrombosis during and after pregnancy.",
"    </p>",
"    <p>",
"     In surgical patients with a moderate to low risk of blood clots, other preventive measures may be used. For example, some surgical patients are fitted with inflatable compression devices that are worn around the legs during and immediately after surgery and periodically fill with air. These devices apply gentle pressure to improve circulation and help prevent clots.",
"    </p>",
"    <p>",
"     Graduated compression stockings may also be recommended; these stockings apply pressure to the lower legs, with the greatest pressure at the ankle. The pressure gradually decreases up to the knee. For all patients, walking as soon as possible after surgery can decrease the risk of a blood clot.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Extended travel",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prolonged travel appears to confer a two- to fourfold increase in risk of venous thromboembolism (VTE) [",
"     <a class=\"abstract\" href=\"UTD.htm?12/44/12998/abstract/2\">",
"      2",
"     </a>",
"     ]. There are a few tips that may be of benefit during extended travel (",
"     <a class=\"graphic graphic_table graphicRef71028 \" href=\"UTD.htm?16/37/16987\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      SPECIAL PRECAUTIONS FOR PEOPLE WITH DEEP VEIN THROMBOSIS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Second thrombosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients being treated for venous thrombosis are at an increased risk for developing another blood clot, although this risk is significantly smaller when heparin or warfarin (Coumadin) is used. The patient should watch for new leg pain, swelling,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     redness. If these symptoms occur, the patient should speak to",
"     <span class=\"nowrap\">",
"      his/her",
"     </span>",
"     healthcare provider or seek medical attention as soon as possible.",
"    </p>",
"    <p>",
"     Other symptoms may indicate that a clot in the leg has broken off and traveled to the lung, causing a pulmonary embolism. These may include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       New chest pain with difficulty breathing",
"      </li>",
"      <li>",
"       A rapid heart rate",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       a feeling of passing out",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This complication may be life-threatening and requires",
"     <strong>",
"      immediate attention",
"     </strong>",
"     . Emergency medical services are available in most areas of the United States by calling 911.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulants such as heparin and warfarin can have serious side effects and should be taken",
"     <strong>",
"      exactly",
"     </strong>",
"     as directed. If a dose is forgotten, the patient should call",
"     <span class=\"nowrap\">",
"      his/her",
"     </span>",
"     provider or clinic for advice. The dose should not be changed to make up for missed doses. Patients should immediately report to the pharmacist or physician if the pill or tablet looks different from the previous bottle. Other precautions are necessary when taking warfarin, and are outlined in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Patients may bleed easily while taking anticoagulants. Bleeding may develop in many areas, such as the nose or gums, excessive menstrual bleeding, bleeding in the urine or feces, bleeding or excessive bruising in the skin, as well as vomiting material that is bright red or like coffee grounds. In some cases, bleeding can develop inside the body and not be noticed immediately. Bleeding inside the body can cause a person to feel faint, or have pain in the back or abdomen. A healthcare provider should be notified immediately if there is any sign of this problem.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Wear an alert tag",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who take warfarin should wear a bracelet, necklace, or similar alert tag at all times. If medical treatment is required and the person is too ill to explain",
"     <span class=\"nowrap\">",
"      his/her",
"     </span>",
"     condition, the tag will alert responders about the patient's use of warfarin and risk of excessive bleeding.",
"    </p>",
"    <p>",
"     The alert tag should list the person's medical conditions, as well as the name and phone number of an emergency contact. One device, Medic Alert, provides a toll-free number that emergency medical workers can call to find out a person's medical history, list of medications, family emergency contact numbers, and healthcare provider names and numbers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h3\">",
"      Reduce the risk of bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some simple modifications can limit the risk of bleeding:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use a soft bristle toothbrush",
"      </li>",
"      <li>",
"       Floss with waxed floss rather than unwaxed floss",
"      </li>",
"      <li>",
"       Shave with an electric razor rather than a blade",
"      </li>",
"      <li>",
"       Take care when using scissors or knives",
"      </li>",
"      <li>",
"       Avoid potentially harmful activities (eg, contact sports)",
"      </li>",
"      <li>",
"       Do not take aspirin or other NSAIDS (eg, ibuprofen, Advil, Aleve, Motrin, Nuprin) unless directed to do so by a healthcare provider. Other nonprescription pain medications, such as acetaminophen, may be a safe alternative.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our website (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287384622\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248133985\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/47/41714?source=see_link\">",
"      Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=see_link\">",
"      Patient information: Knee replacement (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=see_link\">",
"      Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=see_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=see_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/1/12306?source=see_link\">",
"      Patient information: Patent foramen ovale (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/16/21762?source=see_link\">",
"      Patient information: Superficial phlebitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/32/30210?source=see_link\">",
"      Patient information: Vein ablation (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248133993\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=see_link\">",
"      Patient information: The nephrotic syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=see_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=see_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?12/44/12998/abstract/1-9\">",
"      1-9",
"     </a>",
"     ]",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H1570631\">",
"     <span class=\"h1\">",
"      ACKNOWLEDGMENT",
"     </span>",
"    </p>",
"    <p>",
"     UpToDate would like to acknowledge Kenneth A Bauer, MD and Gregory YH Lip, MD, FRCPE, FESC, FACC who contributed to earlier versions of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?12/44/12998?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/1\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/2\">",
"      Kelman CW, Kortt MA, Becker NG, et al. Deep vein thrombosis and air travel: record linkage study. BMJ 2003; 327:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/3\">",
"      Chee YL, Watson HG. Air travel and thrombosis. Br J Haematol 2005; 130:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/4\">",
"      Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/5\">",
"      Hyers TM. Venous thromboembolism. Am J Respir Crit Care Med 1999; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/6\">",
"      Qaseem A, Snow V, Barry P, et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2007; 146:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/7\">",
"      Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007; 146:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/8\">",
"      Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med 2007; 5:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12998/abstract/9\">",
"      Blann AD, Lip GY. Venous thromboembolism. BMJ 2006; 332:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f12_44_12998=[""].join("\n");
var outline_f12_44_12998=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DEEP VEIN THROMBOSIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DEEP VEIN THROMBOSIS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           DEEP VEIN THROMBOSIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           DEEP VEIN THROMBOSIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           DEEP VEIN THROMBOSIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           DEEP VEIN THROMBOSIS PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           SPECIAL PRECAUTIONS FOR PEOPLE WITH DEEP VEIN THROMBOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1570631\">",
"           ACKNOWLEDGMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25343\" title=\"figure 1\">",
"           Deep veins of the leg PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?16/37/16987\" title=\"table 1\">",
"           Travel tips PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f12_44_12999="Fourth cranial nerve (trochlear nerve) palsy in children";
var content_f12_44_12999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fourth cranial nerve (trochlear nerve) palsy in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/12999/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12999/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12999/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/12999/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12999/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12999/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/12999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/12999/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/44/12999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paralytic strabismus or squint is caused by weakness or paralysis of one or more of the extraocular muscles. Dysfunction of the fourth cranial nerve (trochlear nerve) can result from lesions anywhere along its path between the fourth nerve nucleus in the midbrain and the superior oblique muscle within the orbit. These lesions can be congenital or acquired.",
"   </p>",
"   <p>",
"    The manifestations and diagnosis of fourth nerve palsy, also known as superior oblique paralysis and trochlear nerve palsy, are reviewed here. Palsies of the third and sixth cranial nerves are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43046?source=see_link\">",
"     \"Sixth cranial nerve (abducens nerve) palsy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fourth cranial nerve (trochlear nerve) has the longest intracranial course and is the only cranial nerve that has a dorsal exit from the brainstem (",
"    <a class=\"graphic graphic_figure graphicRef54433 \" href=\"UTD.htm?9/5/9297\">",
"     figure 1",
"    </a>",
"    ). It begins in the midbrain at the level of the inferior colliculus as fascicles extending from the fourth nerve nuclei. The trochlear nerves cross as they exit dorsally in the anterior medullary velum. The fourth nerve passes between the superior cerebellar artery and the posterior cerebral artery and runs in the subarachnoid space. It travels within the lateral wall of the cavernous sinus and enters the orbit via the superior orbital fissure to innervate the superior oblique muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. The primary action of the superior oblique muscle is intorsion of the eye, but it has additional eye movements of abduction and depression (",
"    <a class=\"graphic graphic_table graphicRef72952 \" href=\"UTD.htm?37/58/38827\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The long course of the fourth cranial nerve renders it particularly prone to injury from blunt head trauma or compression from changes in intracranial pressure, brain tumors, or swelling anywhere along its course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with fourth nerve palsies may complain of binocular (ie, present with both eyes open) vertical diplopia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subjective tilting of objects (torsional diplopia). This subjective torsion can be measured objectively with a double Maddox rod. The affected eye usually is extorted because the superior oblique muscle is an intorter of the eye. Objects viewed in primary position or especially in down-gaze may appear double (eg, when going down a flight of stairs so that the child does not know which step to select).",
"   </p>",
"   <p>",
"    The patient may adopt an anomalous head position to avoid diplopia because torsional and vertical diplopia often improve with head tilting to the side opposite the paralyzed muscle (",
"    <a class=\"graphic graphic_picture graphicRef63202 \" href=\"UTD.htm?43/41/44696\">",
"     picture 1",
"    </a>",
"    ). As an example, vertical and torsional diplopia in a patient with left fourth nerve palsy improve with the head tilted toward the right. Old photographs may show the long-standing compensatory contralateral head tilt in congenital or long-standing palsies.",
"   </p>",
"   <p>",
"    On examination, an ipsilateral hypertropia (the involved eye is deviated upward) is present because the action of the superior oblique muscle (to move the eye down and in) is weak. The deviation is greater when gaze is in the direction toward the weak muscle. Thus, a right fourth nerve palsy causes greater hypertropia in left gaze. The deviation is greater in ipsilateral head tilt.",
"   </p>",
"   <p>",
"    Patients with a small unilateral superior oblique palsy can present with little or no primary position hypertropia and only positive tilt and gaze tests upon examination. In this setting, it is important to consider the possibility of masked bilateral superior oblique palsies (the primary position deviation is obscured because the bilateral fourth nerve palsies cancel each other out).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of fourth nerve palsy may be differentiated based upon clinical topographic localization (",
"    <a class=\"graphic graphic_table graphicRef80378 \" href=\"UTD.htm?10/26/10668\">",
"     table 2",
"    </a>",
"    ). Fourth nerve palsies can be divided into those that are isolated and those that are accompanied by other contributory neurologic abnormalities (\"nonisolated\"). Nonisolated palsies may be divided into four syndromes based upon the topographical anatomy of the fourth nerve:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A midbrain nuclear or fascicular lesion typically is accompanied by other brainstem symptoms. They may include hemisensory loss, hemiparesis, a central Horner syndrome, or other brainstem cranial neuropathies such as third cranial nerve palsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=see_link\">",
"       \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=see_link\">",
"       \"Horner's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lesions of the subarachnoid space typically are associated with other signs and symptoms including headache, stiff neck, and other cranial nerve abnormalities. However, isolated fourth nerve palsy rarely may be the only finding.",
"     </li>",
"     <li>",
"      Cavernous sinus lesions usually are associated with other localizing signs (eg, third, fifth, or sixth nerve dysfunction, or Horner's syndrome).",
"     </li>",
"     <li>",
"      Orbital lesions usually produce such signs as proptosis, chemosis, and orbital or conjunctival edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common causes of fourth nerve palsies in children are congenital (40 percent), traumatic (34 percent), and idiopathic (23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Differentiating acquired fourth nerve palsy from decompensation of a congenital fourth nerve palsy is important because patients with isolated congenital palsies do not typically require further neurologic evaluation or imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with congenital fourth nerve palsy often are able to compensate for the double vision with a head tilt that minimizes symptoms (",
"    <a class=\"graphic graphic_picture graphicRef63202 \" href=\"UTD.htm?43/41/44696\">",
"     picture 1",
"    </a>",
"    ). The amount of hypertropia may not match the degree of head tilt in fourth nerve palsy for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The head tilt generally compensates for the torsion, but not necessarily the vertical deviation, and some patients may even tilt in the opposite direction to better suppress or ignore the second image",
"     </li>",
"     <li>",
"      Variable amounts of sensory cyclofusion exist in patients, which can obscure or negate the torsion that is seen objectively",
"     </li>",
"     <li>",
"      Some patients tilt their heads to create disparity in the image rather than relieve the deviation (and thus can even be tilting their head in the wrong direction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over time, many patients with congenital fourth nerve palsy have increasing difficulty controlling the symptoms and may present with diplopia. They may insist that this is a new problem, although old photos frequently demonstrate a long-standing head tilt [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/14\">",
"     14",
"    </a>",
"    ]. The following additional features may be present in patients with congenital fourth nerve palsies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of complaints of cyclotropia (subjective image tilting), despite objective fundus excyclotorsion.",
"     </li>",
"     <li>",
"      Large ability to fuse the vertical deviation of the eyes (ie, large vertical fusional amplitudes measuring greater than 6 to 8 prism diopters). In some cases of congenital fourth nerve palsy, the amount of hypertropia may be as high as 20 or 30 prism diopters.",
"     </li>",
"     <li>",
"      Facial asymmetry (hypoplasia of the face on the side of head turn) in long-standing or congenital palsies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The occurrence of congenital fourth nerve palsy has been reported in multiple families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The pedigree analysis of five affected members in one family indicated an autosomal dominant inheritance pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Traumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic fourth nerve palsies, in contrast to traumatic third and sixth nerve palsies, may occur with a relatively mild blow to the head (ie, not associated with loss of consciousness or a skull fracture) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/17\">",
"     17",
"    </a>",
"    ]. Careful examination for bilateral fourth nerve palsies is necessary in every case of fourth nerve palsy caused by trauma; the palsies may be asymmetric [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/18\">",
"     18",
"    </a>",
"    ]. In one series of 270 patients with superior oblique paralysis, one-fourth of all cases caused by trauma had bilateral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic fourth nerve palsies, like idiopathic third and sixth nerve palsies, often present with pain over the eyebrow of the affected eye that stops shortly after the diplopia starts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/2,11,19\">",
"     2,11,19",
"    </a>",
"    ]. When asked to point to the pain, patients usually indicate an area just above the brow on the side of the muscle weakness. Rarely does the pain require medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common causes of fourth nerve palsies include increased intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/20\">",
"     20",
"    </a>",
"    ], tumors of the brainstem or along the course of the fourth nerve (eg, schwannoma), and intracranial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions that can present with similar findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restrictive vertical strabismus",
"     </li>",
"     <li>",
"      Other paretic vertical strabismus",
"     </li>",
"     <li>",
"      Myasthenia gravis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ocular tilt reaction and skew deviation",
"     </li>",
"     <li>",
"      Thyroid ophthalmopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464361117\">",
"    <span class=\"h2\">",
"     Restrictive vertical strabismus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restrictive vertical strabismus can be produced by orbital floor fracture, orbital tumors, orbital pseudotumor, and Graves' ophthalmopathy. Patients with these conditions usually have additional orbital signs, such as proptosis, chemosis, and conjunctival injection. Forced ductions (passive rotation of the eyes with ophthalmic forceps) typically confirm the restrictive nature of the ophthalmoplegia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26790?source=see_link\">",
"     \"Causes of vertical strabismus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464361124\">",
"    <span class=\"h2\">",
"     Other paretic vertical strabismus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paretic vertical strabismus can be produced by a partial third nerve palsy that affects the inferior rectus, superior rectus, or inferior oblique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"    </a>",
"    .) Other features of third nerve palsy (eg, ptosis, deficits in adduction, elevation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depression) demonstrated on examination help to differentiate third from fourth nerve palsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464361131\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis can mimic any painless, pupil-spared, nonproptotic ophthalmoplegia. Other signs of myasthenia gravis, such as ptosis, variability, and fatigue, usually are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464361138\">",
"    <span class=\"h2\">",
"     Ocular tilt reaction and skew deviation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular tilt reaction and skew deviation are vertical misalignments caused by disruption of vestibulo-ocular connections. Similar to fourth nerve palsy, skew deviation presents with hypotropia, cyclotorsion, and head tilt [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, the direction of torsion often is inconsistent with superior oblique paralysis. In the uncooperative child, a photograph of the fundus can be taken to demonstrate the torsion. In addition, ocular torsion and vertical misalignment are position-dependent in skew deviation (decreasing with position change from upright to supine), whereas they are relatively unaffected by position in fourth nerve palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. A positive upright-supine test (vertical strabismus decreases by &ge;50 percent with position change from upright to supine) is highly specific (100 percent) and sensitive (80 percent) for skew deviation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/28\">",
"     28",
"    </a>",
"    ]. Finally, skew deviation typically is accompanied by other posterior fossa signs (eg, other cranial neuropathies, hemisensory loss, or hemiparesis) and more widespread brainstem disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link&amp;anchor=H10#H10\">",
"     \"Supranuclear disorders of gaze in children\", section on 'Skew deviation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464361145\">",
"    <span class=\"h2\">",
"     Thyroid ophthalmopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ophthalmopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Unilateral fourth nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;During gross ductional testing in various directions of gaze, the ocular movements can appear to be full despite weakness of the superior oblique muscle. In some cases, however, the affected eye has reduced infraduction with adduction. The three-step test is performed to make the diagnosis of fourth nerve palsy (",
"    <a class=\"graphic graphic_picture graphicRef63202 \" href=\"UTD.htm?43/41/44696\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/12999/abstract/14,29\">",
"     14,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Step 1 &ndash; Which is the higher (hypertropic) eye? (",
"      <a class=\"graphic graphic_picture graphicRef63202 \" href=\"UTD.htm?43/41/44696\">",
"       picture 1",
"      </a>",
"      ) (see panel B)",
"     </li>",
"     <li>",
"      Step 2 &ndash; Is the hypertropia worse in right or left gaze?",
"     </li>",
"     <li>",
"      Step 3 &ndash; Is the hypertropia worse in right or left head tilt?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The determination of the more hypertropic eye narrows the paretic possibilities to four extraocular muscles (the ipsilateral superior oblique or inferior rectus or the contralateral inferior oblique or superior rectus) as in panel B (",
"    <a class=\"graphic graphic_picture graphicRef63202 \" href=\"UTD.htm?43/41/44696\">",
"     picture 1",
"    </a>",
"    ). As an example, if the left eye is higher (a left hypertropia), the muscles that are potentially involved include the depressors of the left eye, the left superior oblique, and the left inferior rectus; or the elevators of the right eye, the right inferior oblique, and the right superior rectus.",
"   </p>",
"   <p>",
"    The determination of which horizontal gaze worsens the hypertropia narrows the possible muscles involved from four to two because only two muscles act in right gaze and two in left gaze. The hypertropia is worse in contralateral gaze because that movement is controlled by the paretic muscle, as in panel C (",
"    <a class=\"graphic graphic_picture graphicRef63202 \" href=\"UTD.htm?43/41/44696\">",
"     picture 1",
"    </a>",
"    ). Thus, worsening of the hypertropia in right gaze in a patient with left hypertropia implicates either the left superior oblique or the right superior rectus.",
"   </p>",
"   <p>",
"    The determination of which head tilt worsens the hypertropia (Bielschowsky head tilt test) identifies the involved muscle, as in panel D (",
"    <a class=\"graphic graphic_picture graphicRef63202 \" href=\"UTD.htm?43/41/44696\">",
"     picture 1",
"    </a>",
"    ). Hyperdeviation is worse in ipsilateral head tilt in a fourth nerve palsy because the intorsion ability of the ipsilateral superior oblique is weak and is compensated for by the other ipsilateral intorter (the superior rectus). Activation of the superior rectus causes elevation of the eye and increases the hypertropia. The deviation improves in contralateral head tilt, the position that typically is adopted by the patient to reduce diplopia.",
"   </p>",
"   <p>",
"    Some authors advocate for a \"fourth step\" to insure that the typical excyclotorsion of a weak superior oblique muscle is present on the affected side.",
"   </p>",
"   <p>",
"    The upright-supine test is alternative proposed fourth step to differentiate skew deviation from other causes of vertical strabismus. (See",
"    <a class=\"local\" href=\"#H464361138\">",
"     'Ocular tilt reaction and skew deviation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bilateral fourth nerve palsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral fourth nerve palsies are suggested by the following features (",
"    <a class=\"graphic graphic_picture graphicRef60504 \" href=\"UTD.htm?39/18/40230\">",
"     picture 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternating hypertropia on horizontal gaze (eg, right hypertropia in left gaze and left hypertropia in right gaze)",
"     </li>",
"     <li>",
"      Positive head tilt test to either shoulder (double Bielschowsky head tilt test)",
"     </li>",
"     <li>",
"      Large degree of excyclotorsion (&gt;10 degrees)",
"     </li>",
"     <li>",
"      V-pattern esotropia (ie, a difference of 15 prism diopters or more in esotropia between upward and downward gaze) caused by a decrease in the abducting effect of the superior oblique(s) in depression and overaction of the inferior oblique muscle(s)",
"     </li>",
"     <li>",
"      Underaction of both superior oblique muscles",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overaction of both inferior oblique muscles",
"     </li>",
"     <li>",
"      A relatively small hypertropia in primary position (the two eyes have a vertical deviation and tend to cancel each other out)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Measurement of torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torsion is measured objectively with a double Maddox rod. It is important to measure torsion because significant torsion may require torsion surgery (eg, the Harada-Ito procedure). In addition, the torsion may be a limiting factor for fusion even if the vertical and horizontal deviations are corrected surgically or with prism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RADIOLOGIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have nonisolated fourth nerve palsies with neurologic signs or symptoms that localize to the brain stem, subarachnoid space, cavernous sinus, or orbit should undergo neuroimaging to best evaluate the localized area.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) usually is superior to computed tomography (CT) scan for the evaluation of a nonisolated fourth nerve palsy. MRI is more sensitive in the detection of intracranial lesions of the posterior fossa and is not susceptible to the bone artifacts that are seen with CT scanning. CT scanning should be used in patients who require evaluation of bone or acute bleeding, or cannot undergo an MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture may be warranted in patients who have normal imaging studies but are suspected of having subarachnoid space lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link\">",
"     \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"    </a>",
"    .) Evaluation for mimics (eg, myasthenia gravis, thyroid eye disease, skew deviation) may be warranted depending on the clinical presentation, but typically, an isolated fourth nerve palsy is a relatively straightforward clinical diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy should be directed at the underlying etiology of the fourth nerve palsy. The goal is to maximize visual function, including ocular alignment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of the underlying etiology in patients with acquired nontraumatic fourth nerve palsy (eg, brain tumor, increased intracranial pressure) may alleviate the diplopia.",
"     </li>",
"     <li>",
"      Symptomatic patients with isolated palsies that are congenital or traumatic should be considered for treatment. Patients with traumatic fourth nerve palsy, depending upon the severity of the injury to the nerve, may improve over time and often are observed for several months before being considered for treatment. If the palsy does not resolve, the tendency is for it to become comitant. Comitant deviations are those in which the distance between the double images is equal in the various gaze directions and symptoms are only slightly affected by the direction of gaze.",
"     </li>",
"     <li>",
"      Prism therapy may be employed for small, comitant, long-standing deviations. A temporary press-on (Fresnel) prism of sufficient power to align the eyes is placed on the spectacle lens of the affected child. Permanent prisms can be ground into the spectacle lens if the patient is happy with the result and the deviation fails to improve spontaneously.",
"     </li>",
"     <li>",
"      Strabismus surgery may be helpful in patients who fail prism therapy.",
"     </li>",
"     <li>",
"      Patching one eye will alleviate binocular diplopia and is useful for patients who are being observed or who defer prism or surgical therapy. Patching should be employed with caution and with the assistance of an ophthalmology consultant in children in the amblyopic age range. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of amblyopia\", section on 'Definition'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fourth cranial nerve (trochlear nerve) supplies the superior oblique muscle. The actions of the superior oblique muscle include intorsion, abduction, and depression (",
"      <a class=\"graphic graphic_table graphicRef72952 \" href=\"UTD.htm?37/58/38827\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of fourth nerve palsy may include vertical diplopia when both eyes are open, torsional diplopia, extorsion, head tilt (to avoid diplopia), and ipsilateral hypertropia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fourth nerve palsies can be classified as isolated or nonisolated (ie, accompanied by other neurologic abnormalities). Nonisolated palsies are categorized according to the topographical anatomy of the fourth nerve (",
"      <a class=\"graphic graphic_table graphicRef80378 \" href=\"UTD.htm?10/26/10668\">",
"       table 2",
"      </a>",
"      ). The most common causes of fourth nerve palsies in children are congenital, traumatic, and idiopathic. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of fourth nerve palsy includes childhood strabismus, myasthenia gravis, ocular tilt reaction and skew deviation, and thyroid ophthalmopathy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unilateral fourth nerve palsy is diagnosed using the three-step test. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Unilateral fourth nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilateral fourth nerve palsies are suggested by alternating hypertropia on horizontal gaze, positive head tilt test to either shoulder, excyclotorsion &gt;10 degrees, V-pattern esotropia, underaction of both superior oblique muscles",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overaction of both inferior oblique muscles, and a relatively small hypertropia in primary position. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bilateral fourth nerve palsies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who have nonisolated fourth nerve palsies with neurologic signs or symptoms that localize to the brainstem, subarachnoid space, cavernous sinus, or orbit should undergo neuroimaging to best evaluate the localized area. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar puncture may be warranted in patients who have normal imaging studies but are suspected of having subarachnoid space lesions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Additional evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for fourth nerve palsy is directed at the underlying etiology. The goal is to maximize visual function, including ocular alignment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/1\">",
"      Berlit P. Isolated and combined pareses of cranial nerves III, IV and VI. A retrospective study of 412 patients. J Neurol Sci 1991; 103:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/2\">",
"      Burger LJ, Kalvin NH, Smith JL. Acquired lesions of the fourth cranial nerve. Brain 1970; 93:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/3\">",
"      Coppeto JM, Lessell S. Cryptogenic unilateral paralysis of the superior oblique muscle. Arch Ophthalmol 1978; 96:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/4\">",
"      Harley RD. Paralytic strabismus in children. Etiologic incidence and management of the third, fourth, and sixth nerve palsies. Ophthalmology 1980; 87:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/5\">",
"      Keane JR. Fourth nerve palsy: historical review and study of 215 inpatients. Neurology 1993; 43:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/6\">",
"      Khawam E, Scott AB, Jampolsky A. Acquired superior oblique palsy. Diagnosis and management. Arch Ophthalmol 1967; 77:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/7\">",
"      Richards BW, Jones FR Jr, Younge BR. Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves. Am J Ophthalmol 1992; 113:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/8\">",
"      RUCKER CW. Paralysis of the third, fourth and sixth cranial nerves. Am J Ophthalmol 1958; 46:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/9\">",
"      Rucker CW. The causes of paralysis of the third, fourth and sixth cranial nerves. Am J Ophthalmol 1966; 61:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/10\">",
"      Rush JA, Younge BR. Paralysis of cranial nerves III, IV, and VI. Cause and prognosis in 1,000 cases. Arch Ophthalmol 1981; 99:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/11\">",
"      von Noorden GK, Murray E, Wong SY. Superior oblique paralysis. A review of 270 cases. Arch Ophthalmol 1986; 104:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/12\">",
"      Holmes JM, Mutyala S, Maus TL, et al. Pediatric third, fourth, and sixth nerve palsies: a population-based study. Am J Ophthalmol 1999; 127:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/13\">",
"      Helveston EM, Mora JS, Lipsky SN, et al. Surgical treatment of superior oblique palsy. Trans Am Ophthalmol Soc 1996; 94:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/14\">",
"      Brazis PW. Palsies of the trochlear nerve: diagnosis and localization--recent concepts. Mayo Clin Proc 1993; 68:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/15\">",
"      Astle WF, Rosenbaum AL. Familial congenital fourth cranial nerve palsy. Arch Ophthalmol 1985; 103:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/16\">",
"      Botelho PJ, Giangiacomo JG. Autosomal-dominant inheritance of congenital superior oblique palsy. Ophthalmology 1996; 103:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/17\">",
"      Sydnor CF, Seaber JH, Buckley EG. Traumatic superior oblique palsies. Ophthalmology 1982; 89:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/18\">",
"      Kushner BJ. The diagnosis and treatment of bilateral masked superior oblique palsy. Am J Ophthalmol 1988; 105:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/19\">",
"      Younge BR, Sutula F. Analysis of trochlear nerve palsies. Diagnosis, etiology, and treatment. Mayo Clin Proc 1977; 52:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/20\">",
"      Halpern JI, Gordon WH Jr. Trochlear nerve palsy as a false localizing sign. Ann Ophthalmol 1981; 13:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/21\">",
"      M&uuml;ller D, Neubauer BA, Waltz S, Stephani U. Neuroborreliosis and isolated trochlear palsy. Eur J Paediatr Neurol 1998; 2:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/22\">",
"      Carter N, Miller NR. Fourth nerve palsy caused by Ehrlichia chaffeensis. J Neuroophthalmol 1997; 17:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/23\">",
"      Rush JA, Shafrin F. Ocular myasthenia presenting as superior oblique weakness. J Clin Neuroophthalmol 1982; 2:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/24\">",
"      Kim JH, Hwang JM, Hwang YS, et al. Childhood ocular myasthenia gravis. Ophthalmology 2003; 110:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/25\">",
"      Donahue SP, Lavin PJ, Hamed LM. Tonic ocular tilt reaction simulating a superior oblique palsy: diagnostic confusion with the 3-step test. Arch Ophthalmol 1999; 117:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/26\">",
"      Ohashi T, Fukushima K, Chin S, et al. Ocular tilt reaction with vertical eye movement palsy caused by localized unilateral midbrain lesion. J Neuroophthalmol 1998; 18:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/27\">",
"      Parulekar MV, Dai S, Buncic JR, Wong AM. Head position-dependent changes in ocular torsion and vertical misalignment in skew deviation. Arch Ophthalmol 2008; 126:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/28\">",
"      Wong AM, Colpa L, Chandrakumar M. Ability of an upright-supine test to differentiate skew deviation from other vertical strabismus causes. Arch Ophthalmol 2011; 129:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/12999/abstract/29\">",
"      Bixenman WW. Diagnosis of superior oblique palsy. J Clin Neuroophthalmol 1981; 1:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6268 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_12999=[""].join("\n");
var outline_f12_44_12999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Congenital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Traumatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464361117\">",
"      Restrictive vertical strabismus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464361124\">",
"      Other paretic vertical strabismus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464361131\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464361138\">",
"      Ocular tilt reaction and skew deviation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464361145\">",
"      Thyroid ophthalmopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Unilateral fourth nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bilateral fourth nerve palsies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Measurement of torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RADIOLOGIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6268\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6268|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/5/9297\" title=\"figure 1\">",
"      4th nerve anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6268|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/41/44696\" title=\"picture 1\">",
"      Unilateral 4th nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/18/40230\" title=\"picture 2\">",
"      Bilateral 4th nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6268|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/58/38827\" title=\"table 1\">",
"      Actions extraocular muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/26/10668\" title=\"table 2\">",
"      Etiology fourth nerve palsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26790?source=related_link\">",
"      Causes of vertical strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43046?source=related_link\">",
"      Sixth cranial nerve (abducens nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_44_13000="Aldose reductase inhibitors in the prevention of diabetic complications";
var content_f12_44_13000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aldose reductase inhibitors in the prevention of diabetic complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/13000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/13000/contributors\">",
"     Eli A Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/13000/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/13000/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/13000/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/13000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/13000/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/44/13000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/1\">",
"     1",
"    </a>",
"    ], and other studies have demonstrated the central role of hyperglycemia in the pathogenesis of diabetic microvascular complications such as retinopathy, nephropathy, and neuropathy. In addition to degree of hyperglycemia as a risk factor, mounting evidence suggests that both the incidence and severity of diabetic microvasculopathy are modulated by individual genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the molecular basis of how hyperglycemia causes tissue injury is still being defined, two proposed mechanisms, both linked to what has been termed \"oxidative stress,\" are the downstream impact of accumulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    and advanced glycosylation end products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OXIDATIVE STRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxidative stress is strongly implicated as a mediator of multiple diabetes-induced microvascular complications, including nephropathy, retinopathy, and distal symmetric polyneuropathy. Key mediators of glucose-induced oxidative injury are superoxide anions and nitric oxide (NO). One proposed sequence of how hyperglycemia leads to oxidative stress is that high ambient glucose levels increase mitochondrial synthesis of reactive oxygen species, activate protein kinase C (PKC), and overexpress",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    . Superoxides are believed to underlie many of the oxidative changes in hyperglycemic conditions, including increases in aldose reductase and protein kinase C activity.",
"   </p>",
"   <p>",
"    Clinical trials of agents that quench the effects of formed reactive oxygen species in rodents, including vitamin E, C, and alpha-lipoic acid have had limited success in improving cardiovascular outcomes. Statins, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and thiazolinediones may improve cardiovascular outcomes among patients with diabetes by reducing production of reactive oxygen species at a more proximal part of the cascade, thereby more effectively decreasing the oxidative stress burden. Statins and ACE",
"    <span class=\"nowrap\">",
"     inhibitors/ARBs",
"    </span>",
"    appear synergistic in reducing oxidative stress and vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, despite strong evidence that oxidative stress is associated with diabetic complications including nephropathy, retinopathy, and neuropathy, clinical trials of several antioxidants (such as aldose reductase inhibitors, alpha-lipoic acid, vitamins C and E, and growth factors) in diabetic neuropathy and retinopathy, although strongly positive in rodents (with several exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/4\">",
"     4",
"    </a>",
"    ]), have not established therapeutic efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SORBITOL ACCUMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    pathway in this process remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Glucose that enters cells is metabolized in part to sorbitol via the enzyme aldose reductase. Aldose reductase has a low affinity for glucose, and little substrate is processed under physiologic conditions. However, glucose conversion to sorbitol is more pronounced with chronic hyperglycemia. The accumulation of sorbitol within the cells results in a rise in cell osmolality and a decrease in intracellular myoinositol; these changes in turn lead to a decrease in Na-K-ATPase activity and a possible shift in the redox potential within cells. Hyperglycemia may also contribute directly to the decline in cell myoinositol levels by competitively interfering with myoinositol uptake from the extracellular fluid via a sodium-myoinositol cotransporter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In experimental diabetes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    production is markedly enhanced by hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/9\">",
"     9",
"    </a>",
"    ]. The evidence in humans is less clear. Patients with type 2 diabetes, with either proliferative or nonproliferative retinopathy, have significantly higher levels of erythrocyte aldose reductase than patients without retinopathy despite equivalent mean HbA1c and blood pressure levels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, erythrocyte aldose reductase activity in type 2 diabetes has not been found to correlate with age, duration of diabetes, fasting blood glucose, or HbA1c [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenetic importance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    accumulation has been most convincingly demonstrated for diabetic cataracts in rats and mice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/10\">",
"     10",
"    </a>",
"    ]. In humans, the potential value of blocking aldose reductase is suggested by the observation that Brazilian natural medicines for diabetes, named myrciacitrin 1 and myrciaphenone B (made from the leaves of Myricia multi flora DC), are potent inhibitors of both aldose reductase and alpha glucosidase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If this pathway is of more general importance, then inhibiting aldose reductase should reduce microvascular complications. This is an important clinical issue, since it could minimize tissue injury without requiring euglycemia, which is often difficult to attain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANIMAL STUDIES OF ALDOSE REDUCTASE INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens to reduce synthesis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    and other alcohols by inhibition of aldose reductase have been tested in streptozotocin&ndash;(STZ) or alloxan-induced diabetic rats, with occasionally successful results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The aldose reductase inhibitor, sorbinil, minimizes albuminuria and glomerular basement membrane thickening in STZ diabetic rats treated for five months. It also reduces renal cortical activity of glucosyl&ndash;galactosyl&ndash;hydroxylysyl&ndash;glucohydrolase, an enzyme involved in the catabolism of collagen disaccharide units [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In STZ-induced diabetic rats, sorbinil (65",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in the diet) corrected diabetes-induced decreases in endoneurial nutritive blood flow, motor and sensory nerve conduction velocities, and mitochondrial and cytosolic",
"    <span class=\"nowrap\">",
"     NAD+/NADH",
"    </span>",
"    redox imbalances inducing energy deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/17\">",
"     17",
"    </a>",
"    ]. Nerve concentrations of reduced glutathione (GSH) and ascorbate, major non-enzymatic antioxidants, were restored while hyperglycemia-induced lipid peroxidation was completely blocked. The study was interpreted as supporting the thesis that inhibiting increased",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    pathway activity may reverse at least early diabetic neuropathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aldose reductase catalyzes the first and rate-limiting step of the polyol pathway of glucose metabolism. The ability of aldose reductase to alter protein kinase C (PKC) activation in vascular smooth muscle cells (VSMCs) was evaluated in rat aorta isolated and exposed to high glucose in culture [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/18\">",
"       18",
"      </a>",
"      ]. When cultured in a high level of glucose (25",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      but not iso-osmotic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , VSMCs increased membrane-associated PKC activity, which was prevented by tolrestat or sorbinil or by ablation of aldose reductase by small interfering RNA (siRNA) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/18\">",
"       18",
"      </a>",
"      ]. Tolrestat also prevented phosphorylation of PKC-beta2 and -delta. Other experiments in VSCMs reveal that inhibition of aldose reductase, independent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      dehydrogenase, reduced both oxidative stress and hyperglycemic changes in signaling events upstream to the activation of multiple PKC isoforms and PLC-gamma1, suggesting that such therapy might prevent secondary vascular complications of diabetes.",
"     </li>",
"     <li>",
"      Both aldose reductase inhibitors and vasodilators improve nerve conduction velocity in STZ diabetic rats, suggesting a metabolic&ndash;vascular interaction that may be mediated by restoration of impaired nitric oxide synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aldose reductase inhibitors uniformly prevent diabetic cataracts [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/10,20\">",
"       10,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The daily administration of epalrestat, an aldose reductase inhibitor, to STZ diabetic rats prevented gastric erosion and ulceration and normalized gastric mucosal blood flow, an effect also found with a nitric oxide synthase inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/21\">",
"       21",
"      </a>",
"      ]. These results suggest that aldose reductase inhibitors may act, at least in part, by blocking the action of induced nitric oxide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, important negative results have been obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aldose reductase inhibitors do not prevent or improve retinopathy in alloxan&ndash;induced diabetic dogs [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, alloxan&ndash;induced diabetic dogs were treated for five years; there was no evidence of reduced capillary basement membrane thickening in the retina, renal glomerulus, or leg muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS OF ALDOSE REDUCTASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs which block aldose reductase activity include spirohydantoins (sorbinil), carboxylic acid derivatives (tolrestat, ponalrestat, and epalrestat), and flavonoids. Clinical trials over the past decade have assessed the efficacy of these agents in the treatment of diabetic retinopathy, neuropathy, and nephropathy. Although some positive results have been reported, the benefits have generally been minimal and of no substantive clinical importance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/24\">",
"     24",
"    </a>",
"    ]. A review of studies published between 2009 and 2011 found aldose reductase inhibitors safe but ineffective in delaying or preventing diabetic complications such as retinopathy, neuropathy, nephropathy, and cataractogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further compounding this general lack of enthusiasm, sorbinil has been withdrawn from further use because of its severe and frequent toxicity, ponalrestat has not been effective in clinical trials, and tolrestat was withdrawn from the worldwide market in 1998 after the appearance of severe liver toxicity (including one case of hepatic necrosis reported from Italy) and the failure of clinical trials to demonstrate clear benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illustrating the general experience with aldose reductase inhibitors is the Sorbinil Retinopathy Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/27\">",
"     27",
"    </a>",
"    ]. This randomized double-blind study treated 497 patients with insulin-dependent diabetes (IDDM) for a median of 41 months with either sorbinil or placebo; no significant difference was noted between the treatment and placebo groups. Hypersensitivity to sorbinil was noted in about 7 percent of subjects during the first three months of treatment. No final report was issued for the study, which is considered indicative of a negative trial outcome. Ponalrestat, tested in small groups of patients for a shorter time, also showed no benefit in diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/28\">",
"     28",
"    </a>",
"    ], as did a trial of topical corneal administration of an aldose reductase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary reports associate a proclivity to nephropathy in diabetes with polymorphism of the gene(s) coding for aldose reductase in both type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/30\">",
"     30",
"    </a>",
"    ] and type 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/31\">",
"     31",
"    </a>",
"    ] diabetes. Aldose reductase inhibitors may improve some of the manifestations of diabetic nephropathy. In one study, for example, tolrestat (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was given to 20 patients with IDDM after six months of placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/32\">",
"     32",
"    </a>",
"    ]. Tolrestat reversed the glomerular hyperfiltration, lowering the glomerular filtration rate from 156 to 124",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (p&lt;0.001), and decreased the urinary albumin excretion rate from 197 to 158",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (p&lt;0.001). Similar changes have been induced by ponalrestat [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, preliminary studies suggest that aldose reductase inhibitors may not be effective over the long term. In one report, urinary albumin excretion was measured in 16 diabetic subjects who were treated for 12 months with either tolrestat (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or ascorbic acid (500 mg BID) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/34\">",
"     34",
"    </a>",
"    ]. Although ascorbic acid decreased urinary albumin excretion rate after nine months, tolrestat had no effect on proteinuria or other measured variables.",
"   </p>",
"   <p>",
"    On the other hand, epalrestat (150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was evaluated in a study that administered the drug for five years to 35 type 2 diabetic patients presenting with microalbuminuria who were compared with age, gender, and body mass matched diabetic control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/35\">",
"     35",
"    </a>",
"    ]. While blood pressure, HbA1c, and total cholesterol were unchanged in both groups, the control group had significantly increased urinary albumin excretion from 82",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    creatinine at the baseline to 301",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    at the end of the study. There was no change in urinary albumin excretion in the epalrestat-treated group",
"    <span class=\"nowrap\">",
"     (81mg/g",
"    </span>",
"    at baseline and 87",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    by the end of the study). These results were interpreted by the authors as favoring the potential usefulness of aldose reductase inhibitors in the incipient stage of diabetic nephropathy in type 2 diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldose reductase inhibitors have produced inconsistent benefits in diabetic neuropathy. As an example, a double-blind, placebo-controlled trial evaluated the effect of tolrestat withdrawal in 372 patients with IDDM and symptomatic neuropathy who had been treated with tolrestat for a mean of 4.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/36\">",
"     36",
"    </a>",
"    ]. Those patients who were switched to placebo showed progression of motor nerve neuropathy (decreased conduction velocity) and deterioration of vibration threshold. In comparison, those continued on tolrestat remained stable. Symptoms of pain and paresthesias were less prevalent in the tolrestat group.",
"   </p>",
"   <p>",
"    Some benefit of tolrestat in both primary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/37\">",
"     37",
"    </a>",
"    ] and the treatment of symptomatic diabetic neuropathy has been shown in other trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. However, the improvement may be relatively minor and may be seen in a relatively small number of symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/6\">",
"     6",
"    </a>",
"    ]. In one study of over 200 patients with symptomatic neuropathy, for example, a sustained improvement in motor nerve conduction velocity and paresthesias was seen in 28 percent of patients treated with tolrestat (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    versus 5 percent in the placebo group. There was no benefit in neuropathic pain, which improved to an equivalent degree in both groups.",
"   </p>",
"   <p>",
"    A multicenter Canadian double-blind trial involving 549 patients with sensorimotor polyneuropathy who were assigned to treatment with placebo or ranirestat 10, 20, or 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 52 weeks found no significant change in nerve conduction studies and in quantitative sensory tests of bilateral sural plus proximal median sensory nerve conduction velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/42\">",
"     42",
"    </a>",
"    ]. There was significant improvement in the summed motor velocity with ranirestat 20 and 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at 12, 24, and 36 weeks, and in peroneal motor velocity with ranirestat 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at 36 and 52 weeks. The authors concluded that treatment with ranirestat benefits motor but not sensory nerve function in mild to moderate neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/43\">",
"     43",
"    </a>",
"    ]. Ranirestat has been termed the \"most promising\" and \"safe\" of newly introduced aldose reductase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is decreased enthusiasm for aldose reductase inhibitors to prevent or treat diabetic retinopathy since the large Sorbinil Retinopathy Trial showed a lack of important benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/27\">",
"     27",
"    </a>",
"    ]. Although nerve conduction velocities were increased by sorbinil in the peroneal nerve &mdash; but not in the median motor or sensory nerves &mdash; no amelioration of early clinical signs or symptoms of diabetic neuropathy was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/44\">",
"     44",
"    </a>",
"    ]. A similar lack of benefit was observed in a second study in which an autonomic neuropathy was assessed using myocardial scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Encouraging studies in rats prompted clinical trials of fidarestat, an aldose reductase inhibitor. By donating a proton to aldose reductase, fidarestat changes from a neutral to a negative charge, a change that is thought to underlie the mechanism for its inhibitory action [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Control and streptozotocin-induced diabetic rats were treated with or without fidarestat, 16",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, for six weeks after induction of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/47\">",
"     47",
"    </a>",
"    ]. Sciatic motor nerve conduction velocity, hindlimb digital sensory nerve conduction velocity, and sciatic nerve concentrations of two major nonenzymatic antioxidants, glutathione and ascorbate, decreased in diabetic versus control rats, and these changes were prevented by fidarestat. In addition, fidarestat prevented diabetes-induced increase in nitrotyrosine (a marker of peroxynitrite-induced injury) and poly(ADP-ribose)immunoreactivities in both sciatic nerve and retina [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/47\">",
"     47",
"    </a>",
"    ]. These findings underscore the present clinical trials of fidarestat, a specific, potent, and aldose reductase inhibitor.",
"   </p>",
"   <p>",
"    In a study of 279 patients with diabetic neuropathy, patients were randomly assigned to receive placebo or fidarestat (1 mg daily) for 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/48\">",
"     48",
"    </a>",
"    ]. Significant objective improvement in electrophysiological measures of nerve conduction in motor and sensory nerves was observed in the fidarestat group compared with placebo, and all subjective symptoms evaluated (numbness, spontaneous pain, sensation of rigidity, paresthesia in the soles upon walking, heaviness in the foot, and hypesthesia) were also significantly improved in the treated group. No other clinical trials of fidarestat have been reported since 2005.",
"   </p>",
"   <p>",
"    One positive clinical application has been reported in a Japanese trial of epalrestat, an aldose reductase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/49\">",
"     49",
"    </a>",
"    ]. A prospective open-label, multicenter study in which epalrestat and control groups were randomly assigned to either 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    epalrestat daily (289 patients) or a control group (305 patients) for three years, with median nerve conduction velocity (MNCV) taken as the key determinant of efficacy. Epalrestat significantly prevented deterioration of median MNCV while preserving vibration perception threshold seen in the control group (p&lt;0.001). Long-term treatment with epalrestat was well tolerated.",
"   </p>",
"   <p>",
"    Nevertheless, clinical end points for improvement in diabetic neuropathy are difficult to quantitate and caution is appropriate in accepting a positive conclusion from those studies reported to date [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/6\">",
"     6",
"    </a>",
"    ]. With the exception of fidarestat, there has generally been no improvement in pain, an inconsistent effect on paresthesias, and an increase in nerve conduction in some but not all nerves. In an attempt to provide more objective data, sural nerve biopsies are being examined in an ongoing trial of tolrestat in 600 diabetic subjects in the hope that histologic evidence of nerve regeneration may be a marker of drug&ndash;induced improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One newly devised aldose reductase inhibitor, ranirestat, was found to penetrate the sural nerve and inhibit",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    and fructose accumulation in patients with diabetic sensorimotor polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/51\">",
"     51",
"    </a>",
"    ]. No long-term clinical results have yet been reported, although a Phase III trial to test the effectiveness of ranirestat on the course of diabetic complications including neuropathy, cataracts, retinopathy, and nephropathy is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials to demonstrate prevention or amelioration of diabetic neuropathy by aldose reductase inhibitors have proven insufficiently positive to warrant clinical introduction. Current exploration of the benefits of blocking aldose reductase in diabetic patients includes correction of flawed trial design, introduction of improved drugs such as fidarestat, and exploring how the molecular anatomy of an aldose reductase drug relates to its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, aldose reductase inhibitors have not shown convincing evidence of benefit except, perhaps, in some patients with diabetic neuropathy. It is possible that the drug dose was too low (in anticipation of possible toxicity at higher doses) or that the above studies were too short [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/6\">",
"     6",
"    </a>",
"    ]. The microvascular complications of diabetes develop slowly, often taking a decade or longer to become evident clinically. Therefore, an intervention in the early stages of nephropathy, neuropathy, or retinopathy may not be able to detect statistically different differences between treatment groups for years. However, the benefit from aldose reductase inhibitors is not likely to be large. The inability to reproduce in diabetic patients the clear benefit of blunting neuropathy and retinopathy in rodents with induced diabetes has been especially disappointing. Thus, although one in four patients with diabetes is afflicted with distal symmetric polyneuropathy, treatment of the syndrome continues to be an unmet challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the molecular basis for the pathogenesis of diabetic complications is unraveled, an increasingly promising therapy is the administration of two or more synergistic metabolic blockers interfering with, for instance, oxidative stress and protein denaturation. As an example, the expression of retinal vascular endothelial growth factor (VEGF) and development of proliferative retinopathy in galactosemic rats may be prevented by either aminoguanidine or an aldose reductase inhibitor. Since both drugs impede immunocytochemical expression of VGEF, their combined therapy may ultimately retard diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of aldose reductase in mediating angiogenic signals has been examined in culture and in nude mice xenografts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13000/abstract/54\">",
"     54",
"    </a>",
"    ]. In one study the inhibition of aldose reductase prevented vascular endothelial cell growth factor-induced proliferation and expression of oxidative stress-signaling, infiltration of blood cells, invasion, migration and formation of capillary like structures suggesting a possible application in preventing angiogenesis. For now, however, clinical application of aldose reductase inhibitors remains a promise unfulfilled.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/1\">",
"      Leslie RD. United Kingdom prospective diabetes study (UKPDS): what now or so what? Diabetes Metab Res Rev 1999; 15:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/2\">",
"      Szaflik JP, Majsterek I, Kowalski M, et al. Association between sorbitol dehydrogenase gene polymorphisms and type 2 diabetic retinopathy. Exp Eye Res 2008; 86:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/3\">",
"      Rahangdale S, Yeh SY, Malhotra A, Veves A. Therapeutic interventions and oxidative stress in diabetes. Front Biosci 2009; 14:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/4\">",
"      Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 31 Suppl 2:S170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/5\">",
"      Cowell RM, Russell JW. Nitrosative injury and antioxidant therapy in the management of diabetic neuropathy. J Investig Med 2004; 52:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/6\">",
"      Frank RN. The aldose reductase controversy. Diabetes 1994; 43:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/7\">",
"      Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/8\">",
"      Hotta N. New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition. Nagoya J Med Sci 1997; 60:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/9\">",
"      Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol Sci 1994; 15:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/10\">",
"      Nishimura C, Saito T, Ito T, et al. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 1994; 37:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/11\">",
"      Nishimura C, Hotta Y, Gui T, et al. The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy. Diabetes Res Clin Pract 1997; 37:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/12\">",
"      Yoshikawa M, Shimada H, Nishida N, et al. Antidiabetic principles of natural medicines. II. Aldose reductase and alpha-glucosidase inhibitors from Brazilian natural medicine, the leaves of Myrcia multiflora DC. (Myrtaceae): structures of myrciacitrins I and II and myrciaphenones A and B. Chem Pharm Bull (Tokyo) 1998; 46:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/13\">",
"      Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008; 9:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/14\">",
"      Robison WG Jr, Tillis TN, Laver N, Kinoshita JH. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp Eye Res 1990; 50:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/15\">",
"      Sun W, Oates PJ, Coutcher JB, et al. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006; 55:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/16\">",
"      Kassab JP, Guillot R, Andre J, et al. Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional and ultrastructural studies. Biochem Pharmacol 1994; 48:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/17\">",
"      Obrosova IG, Van Huysen C, Fathallah L, et al. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002; 16:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/18\">",
"      Ramana KV, Friedrich B, Tammali R, et al. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes 2005; 54:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/19\">",
"      Stevens MJ, Dananberg J, Feldman EL, et al. The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994; 94:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/20\">",
"      Kador PF, Robison WG Jr, Kinoshita JH. The pharmacology of aldose reductase inhibitors. Annu Rev Pharmacol Toxicol 1985; 25:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/21\">",
"      Suzuki H, Shimosegawa T, Ohara S, Toyota T. Epalrestat prevents the decrease in gastric mucosal blood flow and protects the gastric mucosa in streptozotocin diabetic rats. J Gastroenterol 1999; 34:172.",
"     </a>",
"    </li>",
"    <li>",
"     Kern, TS, Engerman, RL. Development of complications in diabetic dogs and galactosemic dogs: effect of aldose reductase inhibitors. In: Proceedings of a workshop on aldose reductase inhibitors, NIH publication, 1991. p.81&ndash;3114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/23\">",
"      Engerman RL, Kern TS, Garment MB. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition. J Diabetes Complications 1993; 7:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/24\">",
"      Ohmura C, Watada H, Azuma K, et al. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes. Endocr J 2009; 56:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/25\">",
"      Ramana KV. ALDOSE REDUCTASE: New Insights for an Old Enzyme. Biomol Concepts 2011; 2:103.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Pharmaceutical Newsletter N&ordm; 3-4, 12;1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/27\">",
"      A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol 1990; 108:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/28\">",
"      Tromp A, Hooymans JM, Barendsen BC, van Doormaal JJ. The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc Ophthalmol 1991; 78:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/29\">",
"      Nakahara M, Miyata K, Otani S, et al. A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients. Br J Ophthalmol 2005; 89:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/30\">",
"      Lajer M, Tarnow L, Fleckner J, et al. Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabet Med 2004; 21:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/31\">",
"      Zhao HL, Tong PC, Lai FM, et al. Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients. Diabetes 2004; 53:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/32\">",
"      Passariello N, Sepe J, Marrazzo G, et al. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care 1993; 16:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/33\">",
"      Pedersen MM, Christiansen JS, Mogensen CE. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes 1991; 40:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/34\">",
"      McAuliffe AV, Brooks BA, Fisher EJ, et al. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion. Nephron 1998; 80:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/35\">",
"      Iso K, Tada H, Kuboki K, Inokuchi T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications 2001; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/36\">",
"      Santiago JV, Snksen PH, Boulton AJ, et al. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabetes Complications 1993; 7:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/37\">",
"      Giugliano D, Acampora R, Marfella R, et al. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995; 18:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/38\">",
"      Boulton AJ, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990; 33:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/39\">",
"      Macleod AF, Boulton AJ, Owens DR, et al. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group. Diabete Metab 1992; 18:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/40\">",
"      Giugliano D, Marfella R, Quatraro A, et al. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Ann Intern Med 1993; 118:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/41\">",
"      Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999; 53:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/42\">",
"      Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opin Investig Drugs 2008; 17:575.",
"     </a>",
"    </li>",
"    <li>",
"     Bril, V, Hirose, T, Tomioka, S, Buchanan, R; the Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/44\">",
"      The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group. Neurology 1993; 43:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/45\">",
"      Utsunomiya K, Narabayashi I, Tamura K, et al. Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus. Eur J Nucl Med 1998; 25:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/46\">",
"      Zhao HT, Hazemann I, Mitschler A, et al. Unusual binding mode of the 2S4R stereoisomer of the potent aldose reductase cyclic imide inhibitor fidarestat (2S4S) in the 15 K crystal structure of the ternary complex refined at 0.78 A resolution: implications for the inhibition mechanism. J Med Chem 2008; 51:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/47\">",
"      Obrosova IG, Pacher P, Szab&oacute; C, et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 2005; 54:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/48\">",
"      Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001; 24:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/49\">",
"      Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006; 29:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/50\">",
"      Sima AA, Greene DA, Brown MB, et al. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group. J Diabetes Complications 1993; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/51\">",
"      Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004; 27:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/52\">",
"      Rakowitz D, Piccolruaz G, Pirker C, Matuszczak B. Novel aldose reductase inhibitors derived from 6-[[(diphenylmethylene)amino]oxy]hexanoic acid. Arch Pharm (Weinheim) 2007; 340:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/53\">",
"      Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007; 10:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13000/abstract/54\">",
"      Tammali R, Reddy AB, Srivastava SK, Ramana KV. Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis 2011; 14:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3078 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_13000=[""].join("\n");
var outline_f12_44_13000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OXIDATIVE STRESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SORBITOL ACCUMULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANIMAL STUDIES OF ALDOSE REDUCTASE INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL TRIALS OF ALDOSE REDUCTASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_44_13001="Hollow viscus blunt abdominal trauma in children";
var content_f12_44_13001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hollow viscus blunt abdominal trauma in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/13001/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/13001/contributors\">",
"     Mary Jo Haley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/13001/contributors\">",
"     William Middlesworth, MD, FAAP, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/13001/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/13001/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/44/13001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/44/13001/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/44/13001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20396460\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hollow viscus injuries in children resulting from blunt abdominal trauma are usually inflicted by forceful mechanisms that cause serious associated injuries. The diagnosis of hollow viscus injury may be delayed, since the more obvious solid visceral injuries that frequently accompany them are managed nonoperatively, and imaging studies (specifically computed tomographic [CT] scan), when performed soon after the injury, may fail to demonstrate them. Definitive management of children with blunt abdominal trauma who are evaluated for hollow viscus injury depends on clinical findings. Most require surgical intervention. &nbsp;",
"   </p>",
"   <p>",
"    This topic will review blunt hollow visceral injuries in children, including mesenteric injury, duodenal hematoma, and perforation of the stomach, small intestine, and colon. Evaluation and management of traumatic liver, pancreas, and splenic injuries in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4777?source=see_link\">",
"     \"Liver, spleen, and pancreas injury in children with blunt abdominal trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, bowel injuries associated with rectal foreign bodies are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39654?source=see_link&amp;anchor=H18#H18\">",
"     \"Rectal foreign bodies\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396467\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt abdominal trauma occurs frequently in childhood but seldom results in significant hollow visceral injury. The overall frequency of blunt hollow visceral injuries among children in the United States ranges from &lt;1 to 5 percent in large reviews of pediatric blunt abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Injury to the small bowel (specifically jejunal perforation) is seen most commonly, followed by injury to the duodenum, colon, and stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of gastrointestinal (GI) injuries are caused through a discrete point of energy transfer (eg, direct blow, seat belt injury, bicycle handlebar injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/3\">",
"     3",
"    </a>",
"    ]. Motor vehicle accidents are the most prevalent cause in reviews from pediatric trauma centers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/2,4,7-12\">",
"     2,4,7-12",
"    </a>",
"    ]. Falls and bicycle handlebar injuries are other frequent causes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/3,4,7-9,11\">",
"     3,4,7-9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical mechanism for these injuries is rapid acceleration or deceleration of the intestinal structure near a point of anatomic fixation (eg, the ligament of Treitz), or the trapping of bowel between the seat belt and the spine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/13\">",
"     13",
"    </a>",
"    ]. It has been shown that children improperly restrained by ill-fitting seat belts are 4 times more likely to suffer hollow viscus trauma than properly restrained children, and that those with the &ldquo;seat belt sign&rdquo;(an area of ecchymosis or abrasion across the abdomen) are 13 times as likely to have GI trauma than those without it [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7836235\">",
"    <span class=\"h2\">",
"     Child abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hollow viscus injury is also commonly observed in abused children. For example, among 664 children with intraabdominal injury not due to motor vehicle crash reported to the National Pediatric Trauma Registry (United States), hollow viscus injury was seen in 77 percent of children with suspected child abuse versus 23 percent of children injured by other mechanisms, such as a fall, bicycle injury, or unintentional direct blow (OR 13.5, 95% CI: 7.1-25.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/16\">",
"     16",
"    </a>",
"    ]. In other studies, child abuse accounted for 19 to 26 percent of hollow viscus injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/3,6,17\">",
"     3,6,17",
"    </a>",
"    ]. In these cases, the child&rsquo;s caretaker usually denied any injury or reported an implausible mechanism (eg, fall down the stairs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=see_link&amp;anchor=H15#H15\">",
"     \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\", section on 'GI tract injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7836200\">",
"    <span class=\"h2\">",
"     Seat belt syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seventy percent of patients with hollow visceral trauma will have associated injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/1,3,18,19\">",
"     1,3,18,19",
"    </a>",
"    ]. This associated injury most frequently involves the pancreas and seldom involves the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/17\">",
"     17",
"    </a>",
"    ]. The &ldquo;seat belt syndrome&rdquo; is a well described injury pattern that typically includes the combination of a transverse bruise on the abdomen, anterior compression fracture or subluxation of the lumbar spine from hyperflexion, visceral trauma, and, rarely, abdominal aortic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The rate of intraabdominal injury in patients with transverse lap belt-induced bruises ranges from 15 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/17,22\">",
"     17,22",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The poor fit of a lap seat belt in younger children and the anatomic inability of the small pediatric pelvis to properly anchor the lap portion of the belt appear to be risk factors for seat belt syndrome. The belt rides up over the pelvis, into the abdomen, compressing the intraabdominal contents against the spine during rapid deceleration. This injury pattern occurs most commonly in children between three to nine years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with other mechanisms of bowel perforation, the diagnosis of GI tract injury in children with seat belt syndrome is frequently not immediately apparent on physical examination. Consequently, observation and serial exams are recommended for children with a seat belt sign following a motor vehicle crash. In one prospective observational study, 6 of 46 patients with a seat belt sign (ie, a transverse bruise) had no complaint of abdominal pain or tenderness to palpation on initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/15\">",
"     15",
"    </a>",
"    ]. None were subsequently diagnosed with an intraabdominal injury, suggesting that children without abdominal pain and tenderness may be at low risk for a significant GI tract injury, despite the presence of a seat belt sign.",
"   </p>",
"   <p>",
"    Associated extraabdominal injuries (especially head injuries) are the major source of mortality in patients with GI trauma. Mortality from isolated hollow viscus injury varies from 0 percent in some series to near 20 percent in others [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. Death due to peritonitis and sepsis is markedly increased if surgical repair takes place beyond 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10391773\">",
"    <span class=\"h1\">",
"     ANATOMIC ASPECTS OF SPECIFIC INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10391780\">",
"    <span class=\"h2\">",
"     Duodenum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duodenum's location in the retroperitoneum affords it protection, thus significant force must be applied to cause injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/6,25,26\">",
"     6,25,26",
"    </a>",
"    ]. Duodenal injury occurs in 2 to 10 percent of children after blunt abdominal trauma and is a marker for child abuse in children younger than two years of age who do",
"    <strong>",
"     not",
"    </strong>",
"    have a history of serious abdominal trauma along with jejunal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/9,19,27\">",
"     9,19,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=see_link&amp;anchor=H15#H15\">",
"     \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\", section on 'GI tract injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blunt mechanism of injury may cause hematoma or perforation. Duodenal hematomas occur when the duodenum is compressed against the vertebral column. This disrupts blood vessels between the submucosa and the muscularis. The resulting hematoma may cause partial or complete obstruction of the duodenal lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/18\">",
"     18",
"    </a>",
"    ]. Vomiting, the most common symptom, often begins 24 to 48 hours after the time of the injury. Duodenal hematomas are more common in children than adults, and the overwhelming majority will resolve with nonoperative management: nasogastric decompression, bowel rest, and parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/9,18,19,25\">",
"     9,18,19,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Duodenal perforation results from shearing forces and occurs where the fixed portions of the duodenum meet its intraperitoneal segments. Rapid compressive forces can give rise to a sudden, dramatic increase in intraluminal pressure that causes a &ldquo;blowout&rdquo; injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. Perforation is less common than hematoma, and can be difficult to diagnose, especially when it is retroperitoneal, as peritonitis may not be evident [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/11\">",
"     11",
"    </a>",
"    ]. The interval between injury and intervention correlates with morbidity and mortality, so early diagnosis is critical [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/9,19,25,26,29\">",
"     9,19,25,26,29",
"    </a>",
"    ]. Duodenal perforations are always managed operatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10391787\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric injury occurs in only 0.9 to 1.8 percent of children who experience blunt abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. Shielding by the ribcage as well as the distensibility and mobility of the stomach are protective and make injuries to the stomach uncommon. Immediately following a meal, the stomach is distended and extends below the ribcage making it more vulnerable to injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perforation is the most commonly reported gastric injury. In two large retrospective reviews describing gastrointestinal injuries in children, 100 percent of gastric perforations presented with generalized peritonitis and free air on abdominal x-ray, making rapid diagnosis straightforward [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. Gastric perforation mandates surgical repair. The stomach's rich blood supply facilitates healing and direct repair is virtually always successful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/18,28\">",
"     18,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10391794\">",
"    <span class=\"h2\">",
"     Small intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jejunal perforation is the most common hollow viscus injury, occurring in over a third of patients in most retrospective series and when there is no history of significant abdominal trauma, is an injury that is suggestive of child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/2,4,7,10,18,30\">",
"     2,4,7,10,18,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=see_link&amp;anchor=H15#H15\">",
"     \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\", section on 'GI tract injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injuries to the jejunum and ileum are caused by high energy bursting forces or direct blows near fixed points like the ligament of Treitz or the ileocecal valve, and by sudden deceleration resulting in a shearing force at the mesenteric attachment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/18,28\">",
"     18,28",
"    </a>",
"    ]. Mesenteric injuries that compromise the blood supply to the small intestine can lead to delayed perforation from ischemic necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Particularly with the later mechanism, a complaint of pain, tenderness to palpation, or both may only appear after 12 to 24 hours.",
"   </p>",
"   <p>",
"    Peritoneal signs may be less obvious in patients with small bowel injury. Jejunal contents are less irritating than those of the stomach or colon. Small intestinal secretions are much less acidic than gastric juice and have a relatively low bacterial count compared to feces [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Despite this lower bacterial count, complications related to small bowel perforation are primarily infectious (ie, sepsis, intra-abdominal abscess, and wound infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10391801\">",
"    <span class=\"h2\">",
"     Colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colon injuries occur in 2 to 5 percent of pediatric victims of blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/32\">",
"     32",
"    </a>",
"    ]. The transverse colon is susceptible to crush injuries from compression against the spine. The sigmoid colon is tethered at its junction with the rectum, putting it at risk for perforation from rapid deceleration injuries. All segments of the colon are vulnerable to blowout disruption and, excepting the rectum, avulsion from the mesentery. These injuries are evenly distributed throughout the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/28,32\">",
"     28,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colon injuries, like most blunt bowel injuries, are difficult to diagnose. The Eastern Association for the Surgery of Trauma (EAST) Multi-institutional Hollow Viscus Injury Study, a two year review of 96 trauma centers representing 798 patients with blunt",
"    <span class=\"nowrap\">",
"     colonic/rectal",
"    </span>",
"    injury, found no diagnostic test or combination of physical findings that reliably exclude blunt colonic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colonic perforations are always treated operatively. Even with relatively prompt surgery, patients with colon injury are at significantly higher risk of complications than patients with small bowel injury. The same multi-institutional study found a complication rate of 36 percent in patients with colon injury. The majority of these complications were infectious, such as sepsis, wound infection, and abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284039\">",
"    <span class=\"h2\">",
"     Pool suction entrapment and evisceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a rare injury to which children are susceptible due to their small size. There have been 11 reported cases where intestinal prolapse, evisceration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amputation has occurred when a child has sat directly over a pool drain, forming a seal around the drain that applies and centers the negative pressure at the anus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/34\">",
"     34",
"    </a>",
"    ]. The outcome of this potentially serious injury is related to the amount of intestine lost from the prolapse and injury or traumatic amputation. This injury has resulted in intestinal failure and subsequent death from complications of multivisceral transplantation. Entrapment and drowning may also result. Current United States federal legislation regulates the design of pool and spa drains in order to prevent this injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396510\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396519\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of pediatric trauma patients should follow the standard Advanced Trauma Life Support (ATLS) protocol, with life threatening injuries that compromise airway, breathing, and circulation addressed first (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). Assessment for abdominal injury should take place as part of the secondary survey. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H33#H33\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Abdomen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who present with blunt abdominal trauma and signs of hemorrhagic shock that persist despite crystalloid infusion and blood transfusion should undergo exploratory laparotomy without delay. For children with stable hemodynamic status, historical features, physical examination, and selected diagnostic studies may identify or at least raise the clinical suspicion for blunt hollow viscus injury.",
"   </p>",
"   <p>",
"    The presentation of blunt hollow viscus injury is often subtle, and recognition may require a high index of suspicion as well as hospital observation over time for asymptomatic or minimally symptomatic patients deemed to be at high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396526\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following mechanisms are associated with gastrointestinal injury:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Passenger in a high speed motor vehicle crash improperly restrained with a lap belt",
"     </li>",
"     <li>",
"      Fall while riding a bicycle with handlebar injury to the abdomen",
"     </li>",
"     <li>",
"      Direct blow of significant force to the abdomen",
"     </li>",
"     <li>",
"      Child abuse (history is often absent or inadequate to explain the degree of injury) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=see_link&amp;anchor=H15#H15\">",
"       \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\", section on 'GI tract injury'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abdominal pain after blunt abdominal trauma should raise the concern for intraabdominal injury, including hollow viscus disruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396533\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following specific features of the abdominal examination should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal wall ecchymosis or abrasions (&ldquo;seat belt sign&rdquo;)",
"     </li>",
"     <li>",
"      Abdominal tenderness or guarding, diffuse or localized",
"     </li>",
"     <li>",
"      Rebound tenderness",
"     </li>",
"     <li>",
"      Abdominal distention",
"     </li>",
"     <li>",
"      Absent bowel sounds (may indicate a reactive ileus)",
"     </li>",
"     <li>",
"      Upper abdominal mass (duodenal hematoma)",
"     </li>",
"     <li>",
"      Progressive bilious emesis with signs of dehydration (duodenal hematoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gastric decompression with a nasogastric or orogastric tube facilitates abdominal examination and reduces the risk of aspiration of gastric contents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/35\">",
"     35",
"    </a>",
"    ]. The abdominal examination is compromised in patients with impaired neurologic status from head or spinal cord injury or substance abuse and is unreliable in determining the need for further evaluation and intervention in a significant proportion of these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 118 children with blunt trauma who were intubated emergently (&gt;95 percent with altered mental status) found that 14 of 32 children with an intraabdominal injury on computed tomography (CT) had a normal initial abdominal examination during stabilization [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case series of 71 children with head injury and intraabdominal injury discovered on CT or at laparotomy reported a negative physical examination in 30 patients (42 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial physical exam may not reveal convincing signs of hollow viscus injuries. Serial assessments are often required to detect occult intestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/2\">",
"     2",
"    </a>",
"    ]. Children with significant small bowel injuries not detected at initial assessment may demonstrate increased heart rate, fever, decreased urine output, increasing signs of peritoneal irritation, or a combination of these findings within 24 hours of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396540\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952281\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic studies, serum chemistries, and urinalysis are adjuncts to diagnosis, but are not substitutes for clinical assessment and further imaging of children with suspected gastrointestinal trauma. Of the studies often obtained in these children, the following are most likely to assist with patient management:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematocrit",
"     </li>",
"     <li>",
"      White blood cell count",
"     </li>",
"     <li>",
"      Type and cross for packed red blood cells",
"     </li>",
"     <li>",
"      Rapid blood glucose",
"     </li>",
"     <li>",
"      Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])",
"     </li>",
"     <li>",
"      Serum amylase and lipase",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial laboratory studies (eg, white blood cell count, serum glucose, liver enzymes, urinalysis, amylase, lipase) have limited sensitivity and negative predictive value for intraabdominal injuries following blunt abdominal trauma, including gastrointestinal (GI) injury. An observational study evaluated the test characteristics of the &ldquo;routine trauma panel&rdquo;, including complete blood count, serum electrolytes, glucose, liver enzymes, prothrombin time, partial thromboplastin time, and urinalysis in 83 of 241 children with blunt abdominal trauma and evidence of intraabdominal injury on computed tomography (four with GI injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/38\">",
"     38",
"    </a>",
"    ]. No single test had acceptable sensitivity or negative predictive value to be helpful in screening such patients. In this study, glucose and aspartate aminotransferase (AST) had the highest sensitivity (75 and 63 percent, respectively) and lipase had the highest positive predictive value (75 percent).",
"   </p>",
"   <p>",
"    A multicenter observational study of 2249 adult and pediatric patients with small bowel injury and 1895 matched patients without small bowel injury found no difference in initial white blood cell count or hematocrit between the two groups. Serum amylase, although significantly elevated in patients with bowel injury, did not discriminate well between patients with or without bowel injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat assessment of the white blood cell count may provide diagnostic guidance on patients with occult hollow viscus injury. One case series of 46 adult patients with isolated bowel injury found that an elevated white blood cell count within 24 hours of admission had 85 percent sensitivity and 55 percent specificity as an indicator of isolated intestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies commonly obtained in unstable pediatric blunt trauma victims include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H22#H22\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Laboratory studies'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet and differential counts",
"     </li>",
"     <li>",
"      Prothrombin time (PT), partial thromboplastic time (PTT), and international normalized ratio (INR)",
"     </li>",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Serum blood urea nitrogen (BUN) and creatinine",
"     </li>",
"     <li>",
"      Arterial or venous blood gas",
"     </li>",
"     <li>",
"      Blood ethanol level and urine screen for drugs of abuse (adolescents)",
"     </li>",
"     <li>",
"      Urine pregnancy test (postmenarchal females)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952288\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain films of the chest and abdomen may diagnose bowel perforation if free air is present. However, this finding is present in less than 33 percent of patients with gastrointestinal injury after blunt abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/2,11,39\">",
"     2,11,39",
"    </a>",
"    ]. Pneumatosis intestinalis and portal vein gas have been seen in association with child abuse among children who are not brought promptly to medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In patients with duodenal hematoma, plain abdominal radiographs often have nonspecific findings. Because the obstruction is proximal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    partial, the typical radiographic signs of intestinal obstruction (eg, air-fluid levels, dilated loops of bowel) may be absent. However, a duodenal mass can be demonstrated on upper gastrointestinal contrast series or abdominal ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal CT is the best imaging test in children with suspected intraabdominal injury. The indications for abdominal CT in children with blunt abdominal trauma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extravasation of oral contrast, free intra- or retroperitoneal air indicate GI perforation on abdominal CT, but these findings are present less than 50 percent of the time in children with hollow viscus injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/2,39,44\">",
"     2,39,44",
"    </a>",
"    ]. Bowel wall thickening, multiple fluid filled loops, mesenteric streaking, and free fluid in the absence of solid organ injury are also suggestive of intestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. However, blunt gastrointestinal injury is frequently NOT demonstrated on abdominal CT on the initial evaluation at the time of injury. For example, in one study, only 8 of 20 children with blunt bowel or mesenteric injury had abnormal findings on abdominal CT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/47\">",
"     47",
"    </a>",
"    ]. In a larger series of 106 children and adults with gastrointestinal injuries, 76 percent had suggestive findings on helical CT without oral contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, a negative abdominal CT cannot be used to reliably exclude hollow viscus injury after blunt abdominal trauma and must be correlated with clinical and laboratory findings.",
"   </p>",
"   <p>",
"    Focused assessment with sonography for trauma (FAST) is a rapid ultrasound examination of four abdominal locations: right upper quadrant, left upper quadrant, subxiphoid region, and pelvis. The primary utility of this examination for the unstable trauma patient is the detection of hemopericardium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraperitoneal fluid secondary to intraabdominal injury (IAI). For example, persistently unstable patients with blunt abdominal trauma and intraperitoneal fluid on FAST may warrant operative intervention in lieu of computed tomography (CT) of the abdomen. In the stable patient, the presence of intraperitoneal fluid on FAST indicates the need for abdominal CT. However, a negative FAST does not alone have adequate sensitivity or specificity to exclude intraabdominal injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H24#H24\">",
"     \"Trauma management: Approach to the unstable child\", section on 'FAST (Focused Assessment with Sonography for Trauma)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953548\">",
"    <span class=\"h3\">",
"     Diagnostic peritoneal lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic peritoneal lavage is rarely, if ever, performed in hemodynamically stable children with blunt abdominal injury. In addition, it allows introduction of air and fluid into the abdomen, complicating the interpretation of subsequent examinations and imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396547\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of children with suspected blunt hollow viscus injuries should adhere to ATLS protocol for diagnosis and treatment of immediately life-threatening injuries and appropriate resuscitation (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). After the patient has been assessed, resuscitated, and stabilized the patient should receive ongoing care directed by a trauma surgeon with pediatric expertise, when available. Because optimal care and outcomes occur when the critically injured child is initially resuscitated and subsequently managed in a pediatric trauma center (PTC), it is preferable to provide initial care in such facilities from the outset, whenever possible, or to arrange transfer to a PTC for ongoing management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H44#H44\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Definitive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive management of children with blunt abdominal trauma who are evaluated for hollow viscus injury depends on clinical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamically unstable children with suspected hollow viscus injury after blunt abdominal trauma who do not respond to intravenous crystalloid infusions and blood transfusion should undergo emergent exploratory laparotomy.",
"     </li>",
"     <li>",
"      Hemodynamically stable children with blunt abdominal trauma and clear signs of hollow viscus injury on physical exam or imaging (eg, peritonitis, free air on abdominal radiograph or CT) should receive urgent laparoscopy or laparotomy. (See",
"      <a class=\"local\" href=\"#H10391032\">",
"       'Operative management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hemodynamically stable children with suspected injury (eg, concerning history, abdominal ecchymosis or tenderness) but no definite signs of hollow viscus injury (eg, normal or minimally changed laboratory studies and normal or nonspecific findings on imaging) should be admitted to the hospital for observation. These patients should have nothing by mouth and should be maintained on intravenous fluids until intestinal injury is excluded. The diagnosis relies upon clinical suspicion and a combination of findings, such as fever, tachycardia, increasing abdominal pain, and leukocytosis. Return of bowel function in an asymptomatic child reliably excludes GI injury [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients diagnosed with duodenal hematomas warrant admission for nasogastric decompression and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      . They are usually managed nonoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain should be adequately managed in children undergoing evaluation for hollow viscus trauma both before and after operation. Intravenous opioid medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose: 10 mg) typically provide good analgesia. Although there is no evidence specific to analgesia in children with hollow viscus injury due to blunt trauma, data from children with appendicitis suggests that analgesia does not mask symptoms are prevent identification of those patients in need of surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H2654866#H2654866\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Approach and analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25544140\">",
"    <span class=\"h2\">",
"     Child protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a hollow viscus abdominal injury in a child with a questionable mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, subspecialist physician), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for suspected child abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H4#H4\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Mandatory reporting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the medical care team should ensure that children under two years of age with suspected intentional trauma undergo funduscopic examination by an ophthalmologist to assess for retinal hemorrhages and skeletal survey to identify other injuries once the patient's clinical status is stabilized. The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10391032\">",
"    <span class=\"h1\">",
"     OPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard treatment for patients with visceral perforation has been laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/46,49\">",
"     46,49",
"    </a>",
"    ]. In children who are hemodynamically unstable, it remains the safest and best choice. However, exploratory laparotomy is not without risk and complications, including morbidity (eg, postoperative infection, long term risk of adhesive bowel obstruction) and rarely, mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In hemodynamically stable children, laparoscopy plays an increasing role for both diagnosis and treatment of hollow viscus injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/46,49\">",
"     46,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For example, a five year retrospective review of a level I pediatric trauma center database found that initial laparoscopic exploration was performed in 32 of 113 children undergoing abdominal exploration. Twelve of the 32 patients had either no injury or none requiring further intervention, 6 underwent laparoscopic repair of an injury, and 14 underwent open repair. Thus, 18 of 32 patients were spared non-therapeutic laparotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of 50 children with blunt bowel injury, 14 underwent laparoscopy. In six patients, an open procedure was avoided despite the diagnosis of a bowel perforation. No complications occurred in children treated with laparoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of procedure, the following remain indications for surgical exploration in children with blunt abdominal trauma:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Replacement of &gt;40",
"      <span class=\"nowrap\">",
"       ml/kg",
"      </span>",
"      blood products",
"     </li>",
"     <li>",
"      Peritonitis",
"     </li>",
"     <li>",
"      Free intraperitoneal air or extravasated contrast on imaging",
"     </li>",
"     <li>",
"      Clinical deterioration during observation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10392495\">",
"    <span class=\"h2\">",
"     Time to surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of hollow viscus injury is challenging. Initial examinations may be negative or unreliable due to subtlety of presentation, young age, or distracting injuries. Diagnostic studies may be inconclusive. The degree to which timing of surgery affects outcome is controversial. Several studies have not found an association between complications, such as death, wound infection, intraabdominal abscess and time to surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter observational study of 214 children with perforation of the gastrointestinal tract found no correlation between time to surgery and complications, including death, wound infection, intraabdominal abscess, and postoperative bowel obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bensard and coauthors reported a series of 168 children admitted for nonoperative management of blunt abdominal trauma, and found no increase in complications, ICU, or hospital stay despite up to a 56 hour delay in diagnosis in 6 of 9 children with bowel injury [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Moss et al reported 48 patients with small bowel trauma and found no difference in the complication rate between patients with a time to operation of 2.8 hours and those with a 17.4 hour time to operation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies suggest that significant morbidity and mortality may be associated with even minimally prolonged time to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/4,7,31,45\">",
"     4,7,31,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multi-center review of level I and II trauma centers that identified 198 patients with small bowel perforations found that mortality rate increased with length of time to operation in patients with isolated small bowl injury, jumping from 2 to 9 percent after 8 hours, to 16 percent after 16 hours, and to greater than 30 percent after 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of 79 patients with GI injury found no difference in ICU or hospital stay or mortality in patients diagnosed in less than 4 hours versus 24 hours or more. The complication rate, however, was greater in the delayed group (23 percent versus 2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of whether or not an association between time to surgery and complications exists, the risk of morbidity and mortality related to undiagnosed hollow viscus injury is real, and the goal must be to establish a diagnosis as expeditiously as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396554\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of hollow viscus injury include hemorrhagic shock, peritonitis, wound infection, abscess formation, septic shock, and adhesions or stricture with bowel obstruction. Peritonitis is more common in patients with perforations of the stomach or colon. Wound infection, abscess formation, and septic shock may be associated with increasing time to surgery although evidence is conflicting. (See",
"    <a class=\"local\" href=\"#H10391032\">",
"     'Operative management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396568\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients without severe associated injuries have a good outcome after blunt hollow viscus injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/10\">",
"     10",
"    </a>",
"    ]. Return to oral feeding and length of hospital stay varies greatly with the severity of the bowel injury, complications, and associated injuries. Injuries to the stomach and small intestine are usually straight forward to repair and unless there is massive contamination or devascularization, primary repair or resection with anastomosis is standard [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/28\">",
"     28",
"    </a>",
"    ]. Colon injuries may require colostomy if significant fecal contamination is present; however, isolated colon injuries can usually be primarily repaired at the initial surgery, avoiding the complications of stomas and reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/44/13001/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20396575\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hollow viscus injuries (ie, mesenteric injury; duodenal hematoma; and perforation of the stomach, small intestine, and colon) result from discrete point of energy transfers, such as those related to inappropriately applied seat belts during motor vehicle crashes, bicycle handlebars and direct blows. Hollow viscus injury is also frequently observed in abused children. (See",
"      <a class=\"local\" href=\"#H20396467\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial evaluation of pediatric trauma patients should follow the standard Advanced Trauma Life Support (ATLS) protocol, with life threatening injuries that compromise airway, breathing, and circulation addressed first (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"       figure 1",
"      </a>",
"      ). Assessment for abdominal injury should take place as part of the secondary survey. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H33#H33\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Abdomen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children who present with hemodynamic instability after blunt abdominal trauma that does not respond to crystalloid infusion and blood transfusion should undergo exploratory laparotomy without delay. Focused assessment with sonography for trauma (FAST) may provide diagnostic assistance in these patients. (See",
"      <a class=\"local\" href=\"#H952288\">",
"       'Imaging'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The presentation of blunt hollow viscus injury is often subtle, and recognition may require a high index of suspicion as well as hospital observation over time for asymptomatic or minimally symptomatic patients deemed to be at high risk. (See",
"      <a class=\"local\" href=\"#H20396519\">",
"       'Initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with stable hemodynamic status, injury mechanism, physical examination, and selected diagnostic studies may identify or at least raise the clinical suspicion for blunt hollow viscus injury. However, history, physical examination, and laboratory studies have limited sensitivity and negative predictive value for hollow viscus injury. (See",
"      <a class=\"local\" href=\"#H20396526\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20396533\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H952281\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal CT is the best imaging test in children with suspected intraabdominal injury. The indications for abdominal CT in children with blunt abdominal trauma are discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H952288\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A CT scan in the stable child with a blunt abdominal injury may establish the diagnosis of hollow viscus injury when free air or extravasated contrast is seen. However, a negative study does not exclude the diagnosis, especially in patients with concerning physical findings (eg, abdominal tenderness or distension, decreased bowel sounds, or vomiting). Repeated physical examinations may be the most sensitive tool for identifying hollow viscus injuries in such patients. (See",
"      <a class=\"local\" href=\"#H20396533\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H952288\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the patient has been assessed, resuscitated, and stabilized the child should receive ongoing care directed by a trauma surgeon with pediatric expertise, when available. Because optimal care and outcomes occur when the critically injured child is initially resuscitated and subsequently managed in a pediatric trauma center (PTC), it is preferable to provide initial care in such facilities from the outset, whenever possible, or to arrange transfer to a PTC for ongoing management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H44#H44\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Definitive care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Definitive management of children with blunt abdominal trauma who are evaluated for hollow viscus injury depends upon clinical findings, including hemodynamic status and underlying injury. Appropriate analgesia (eg",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      0.1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose: 10 mg) should be provided both before and after operative care. (See",
"      <a class=\"local\" href=\"#H20396547\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10391032\">",
"       'Operative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of a hollow viscus abdominal injury in a child with a questionable mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, subspecialist physician), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for suspected child abuse. (See",
"      <a class=\"local\" href=\"#H25544140\">",
"       'Child protection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H4#H4\">",
"       \"Child abuse: Social and medicolegal issues\", section on 'Mandatory reporting'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/1\">",
"      Allen GS, Moore FA, Cox CS Jr, et al. Hollow visceral injury and blunt trauma. J Trauma 1998; 45:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/2\">",
"      Bensard DD, Beaver BL, Besner GE, Cooney DR. Small bowel injury in children after blunt abdominal trauma: is diagnostic delay important? J Trauma 1996; 41:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/3\">",
"      Canty TG Sr, Canty TG Jr, Brown C. Injuries of the gastrointestinal tract from blunt trauma in children: a 12-year experience at a designated pediatric trauma center. J Trauma 1999; 46:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/4\">",
"      Jerby BL, Attorri RJ, Morton D Jr. Blunt intestinal injury in children: the role of the physical examination. J Pediatr Surg 1997; 32:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/5\">",
"      Ciftci AO, Tanyel FC, Salman AB, et al. Gastrointestinal tract perforation due to blunt abdominal trauma. Pediatr Surg Int 1998; 13:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/6\">",
"      Gaines BA, Shultz BS, Morrison K, Ford HR. Duodenal injuries in children: beware of child abuse. J Pediatr Surg 2004; 39:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/7\">",
"      Holland AJ, Cass DT, Glasson MJ, Pitkin J. Small bowel injuries in children. J Paediatr Child Health 2000; 36:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/8\">",
"      Albanese CT, Meza MP, Gardner MJ, et al. Is computed tomography a useful adjunct to the clinical examination for the diagnosis of pediatric gastrointestinal perforation from blunt abdominal trauma in children? J Trauma 1996; 40:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/9\">",
"      Desai KM, Dorward IG, Minkes RK, Dillon PA. Blunt duodenal injuries in children. J Trauma 2003; 54:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/10\">",
"      Moss RL, Musemeche CA. Clinical judgment is superior to diagnostic tests in the management of pediatric small bowel injury. J Pediatr Surg 1996; 31:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/11\">",
"      Ulman I, Avano��lu A, Ozcan C, et al. Gastrointestinal perforations in children: a continuing challenge to nonoperative treatment of blunt abdominal trauma. J Trauma 1996; 41:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/12\">",
"      Trokel M, DiScala C, Terrin NC, Sege RD. Blunt abdominal injury in the young pediatric patient: child abuse and patient outcomes. Child Maltreat 2004; 9:111.",
"     </a>",
"    </li>",
"    <li>",
"     Saladino RA, Lund DP. Abdominal trauma. In: Textbook of Pediatric Emergency Medicine, 6th, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.1271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/14\">",
"      Lutz N, Arbogast KB, Cornejo RA, et al. Suboptimal restraint affects the pattern of abdominal injuries in children involved in motor vehicle crashes. J Pediatr Surg 2003; 38:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/15\">",
"      Sokolove PE, Kuppermann N, Holmes JF. Association between the \"seat belt sign\" and intra-abdominal injury in children with blunt torso trauma. Acad Emerg Med 2005; 12:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/16\">",
"      Trokel M, Discala C, Terrin NC, Sege RD. Patient and injury characteristics in abusive abdominal injuries. Pediatr Emerg Care 2006; 22:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/17\">",
"      Nance ML, Keller MS, Stafford PW. Predicting hollow visceral injury in the pediatric blunt trauma patient with solid visceral injury. J Pediatr Surg 2000; 35:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/18\">",
"      Grosfeld JL, Rescorla FJ, West KW, Vane DW. Gastrointestinal injuries in childhood: analysis of 53 patients. J Pediatr Surg 1989; 24:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/19\">",
"      Shilyansky J, Pearl RH, Kreller M, et al. Diagnosis and management of duodenal injuries in children. J Pediatr Surg 1997; 32:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/20\">",
"      Newman KD, Bowman LM, Eichelberger MR, et al. The lap belt complex: intestinal and lumbar spine injury in children. J Trauma 1990; 30:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/21\">",
"      Choit RL, Tredwell SJ, Leblanc JG, et al. Abdominal aortic injuries associated with chance fractures in pediatric patients. J Pediatr Surg 2006; 41:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/22\">",
"      Lutz N, Nance ML, Kallan MJ, et al. Incidence and clinical significance of abdominal wall bruising in restrained children involved in motor vehicle crashes. J Pediatr Surg 2004; 39:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/23\">",
"      Durbin DR, Arbogast KB, Moll EK. Seat belt syndrome in children: a case report and review of the literature. Pediatr Emerg Care 2001; 17:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/24\">",
"      Watts DD, Fakhry SM, EAST Multi-Institutional Hollow Viscus Injury Research Group. Incidence of hollow viscus injury in blunt trauma: an analysis from 275,557 trauma admissions from the East multi-institutional trial. J Trauma 2003; 54:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/25\">",
"      Clendenon JN, Meyers RL, Nance ML, Scaife ER. Management of duodenal injuries in children. J Pediatr Surg 2004; 39:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/26\">",
"      Timaran CH, Daley BJ, Enderson BL. Role of duodenography in the diagnosis of blunt duodenal injuries. J Trauma 2001; 51:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/27\">",
"      Sowrey L, Lawson KA, Garcia-Filion P, et al. Duodenal injuries in the very young: child abuse? J Trauma Acute Care Surg 2013; 74:136.",
"     </a>",
"    </li>",
"    <li>",
"     Stylianos, S, Pearl, SH. Abdominal Trauma. In: Pediatric Surgery, Grosfield, JL, Fonkalsrud, EW, Coran, AG (Eds), Elsevier, Philadelphia  p.295.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/29\">",
"      Kunin JR, Korobkin M, Ellis JH, et al. Duodenal injuries caused by blunt abdominal trauma: value of CT in differentiating perforation from hematoma. AJR Am J Roentgenol 1993; 160:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/30\">",
"      Ozt&uuml;rk H, Onen A, Ot&ccedil;u S, et al. Diagnostic delay increases morbidity in children with gastrointestinal perforation from blunt abdominal trauma. Surg Today 2003; 33:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/31\">",
"      Fakhry SM, Brownstein M, Watts DD, et al. Relatively short diagnostic delays (&lt;8 hours) produce morbidity and mortality in blunt small bowel injury: an analysis of time to operative intervention in 198 patients from a multicenter experience. J Trauma 2000; 48:408.",
"     </a>",
"    </li>",
"    <li>",
"     Burch, JM. Injury to the Colon and Rectum. In: Trauma, Feliciano, DV, Moore, EE, Mattox, KL (Eds), Appleton &amp; Lange, Stamford 1996. p.595.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/33\">",
"      Williams MD, Watts D, Fakhry S. Colon injury after blunt abdominal trauma: results of the EAST Multi-Institutional Hollow Viscus Injury Study. J Trauma 2003; 55:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/34\">",
"      Juern J, Schmeling D, Feltis B. Transanal wading pool suction-drain injury resulting in complete evisceration of the small intestine: case report and review of the literature. J Pediatr Surg 2010; 45:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/35\">",
"      Rance CH, Singh SJ, Kimble R. Blunt abdominal trauma in children. J Paediatr Child Health 2000; 36:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/36\">",
"      Flood RG, Mooney DP. Rate and prediction of traumatic injuries detected by abdominal computed tomography scan in intubated children. J Trauma 2006; 61:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/37\">",
"      Miller D, Garza J, Tuggle D, et al. Physical examination as a reliable tool to predict intra-abdominal injuries in brain-injured children. Am J Surg 2006; 192:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/38\">",
"      Capraro AJ, Mooney D, Waltzman ML. The use of routine laboratory studies as screening tools in pediatric abdominal trauma. Pediatr Emerg Care 2006; 22:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/39\">",
"      Fakhry SM, Watts DD, Luchette FA, EAST Multi-Institutional Hollow Viscus Injury Research Group. Current diagnostic approaches lack sensitivity in the diagnosis of perforated blunt small bowel injury: analysis from 275,557 trauma admissions from the EAST multi-institutional HVI trial. J Trauma 2003; 54:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/40\">",
"      Harris HW, Morabito DJ, Mackersie RC, et al. Leukocytosis and free fluid are important indicators of isolated intestinal injury after blunt trauma. J Trauma 1999; 46:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/41\">",
"      Gurland B, Dolgin SE, Shlasko E, Kim U. Pneumatosis intestinalis and portal vein gas after blunt abdominal trauma. J Pediatr Surg 1998; 33:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/42\">",
"      Wu JW, Chen MY, Auringer ST. Portal venous gas: an unusual finding in child abuse. J Emerg Med 2000; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/43\">",
"      Mueller GP, Cassady CI, Dietrich RB, et al. Pediatric case of the day. Occult child abuse (manifesting with pneumatosis intestinalis and portal venous gas). Radiographics 1994; 14:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/44\">",
"      Strouse PJ, Close BJ, Marshall KW, Cywes R. CT of bowel and mesenteric trauma in children. Radiographics 1999; 19:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/45\">",
"      Kurkchubasche AG, Fendya DG, Tracy TF Jr, et al. Blunt intestinal injury in children. Diagnostic and therapeutic considerations. Arch Surg 1997; 132:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/46\">",
"      Feliz A, Shultz B, McKenna C, Gaines BA. Diagnostic and therapeutic laparoscopy in pediatric abdominal trauma. J Pediatr Surg 2006; 41:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/47\">",
"      Peters E, LoSasso B, Foley J, et al. Blunt bowel and mesenteric injuries in children: Do nonspecific computed tomography findings reliably identify these injuries? Pediatr Crit Care Med 2006; 7:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/48\">",
"      Holmes JF, Offerman SR, Chang CH, et al. Performance of helical computed tomography without oral contrast for the detection of gastrointestinal injuries. Ann Emerg Med 2004; 43:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/49\">",
"      Streck CJ, Lobe TE, Pietsch JB, Lovvorn HN 3rd. Laparoscopic repair of traumatic bowel injury in children. J Pediatr Surg 2006; 41:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/44/13001/abstract/50\">",
"      Letton RW, Worrell V, APSA Committee on Trauma Blunt Intestinal Injury Study Group. Delay in diagnosis and treatment of blunt intestinal injury does not adversely affect prognosis in the pediatric trauma patient. J Pediatr Surg 2010; 45:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13898 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_13001=[""].join("\n");
var outline_f12_44_13001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20396575\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20396460\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20396467\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7836235\">",
"      Child abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7836200\">",
"      Seat belt syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10391773\">",
"      ANATOMIC ASPECTS OF SPECIFIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10391780\">",
"      Duodenum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10391787\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10391794\">",
"      Small intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10391801\">",
"      Colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284039\">",
"      Pool suction entrapment and evisceration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20396510\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20396519\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20396526\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20396533\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20396540\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H952281\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H952288\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H953548\">",
"      - Diagnostic peritoneal lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20396547\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25544140\">",
"      Child protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10391032\">",
"      OPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10392495\">",
"      Time to surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20396554\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20396568\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20396575\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13898|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=related_link\">",
"      Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4777?source=related_link\">",
"      Liver, spleen, and pancreas injury in children with blunt abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39654?source=related_link\">",
"      Rectal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_44_13002="Ventricular bigeminy tutorial";
var content_f12_44_13002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1125px;\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Ventricular bigeminy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ventricular beat follows each sinus beat and the coupling interval between the ventricular beat and the previous sinus QRS complex is constant (fixed coupling interval).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_13002=[""].join("\n");
var outline_f12_44_13002=null;
var title_f12_44_13003="2ndary Retroperitoneal fibrosis";
var content_f12_44_13003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of secondary retroperitoneal fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs",
"       </td>",
"       <td>",
"        Methysergide, pergolide, bromocriptine, ergotamine, methyldopa, hydralazine, analgesics, &beta;-blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant diseases",
"       </td>",
"       <td>",
"        Carcinoid, Hodgkin's and non-Hodgkin's lymphomas, sarcomas, carcinomas of the colon, prostate, breast, stomach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections",
"       </td>",
"       <td>",
"        Tuberculosis, histoplasmosis, actinomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiotherapy",
"       </td>",
"       <td>",
"        Testicular seminoma, colon carcinoma, pancreatic carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery",
"       </td>",
"       <td>",
"        Lymphadenectomy, colectomy, hysterectomy, aortic aneurysmectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Others",
"       </td>",
"       <td>",
"        Histiocytoses, Erdheim-Chester disease, amyloidosis, trauma, barium enema",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vaglio, A. Retroperitoneal Fibrosis. Lancet 2006; 367:241. Copyright &copy; Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_13003=[""].join("\n");
var outline_f12_44_13003=null;
var title_f12_44_13004="Knee anterior pain ddx";
var content_f12_44_13004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of anterior knee pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patellofemoral osteoarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OsGood Schlatter's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinding Larsen Johansson syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic bipartite patella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteochondritis dissecans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Synovium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pigmented villonodular synovitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Retinaculum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patellar instability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Skin/bursa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prepatellar bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pes anserine bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Illiotibial band syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hoffa's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saphenous neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Muscle/tendon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quadriceps tendinopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patellar tendinopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Referred pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Lumbar spine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Discogenic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Slipped capital femoral epiphysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Legg calve perthes disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_13004=[""].join("\n");
var outline_f12_44_13004=null;
var title_f12_44_13005="Scrn CRC USPSTF recs";
var content_f12_44_13005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Screening for colorectal cancer: Clinical summary of US Preventive Services Task Force recommendation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td colspan=\"4\">",
"       This document is a summary of the 2008 recommendation of the US Preventive Services Task Force (USPSTF) on screening for colorectal cancer. This summary is intended for use by primary care clinicians.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Population",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adults age 50 to 75*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adults age 76 to 85 years*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adults older than 85*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Recommendation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       <strong>",
"        Screen with high sensitivity fecal occult blood testing (FOBT)#, sigmoidoscopy, or colonoscopy.",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        Do not screen routinely",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        Do not screen",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       For all populations, evidence is insufficient to assess the benefits and harms of screening with computerized tomography colonography (CTC) and fecal DNA testing.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Screening tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"      <td colspan=\"3\">",
"       High sensitivity FOBT, sigmoidoscopy with FOBT, and colonoscopy are effective in decreasing colorectal cancer mortality.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       The risks and benefits of these screening methods vary.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Colonoscopy and flexible sigmoidoscopy (to a lesser degree) entail possible serious complications.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Screening test intervals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       &nbsp;",
"      </td>",
"      <td class=\"sublist1_start\" colspan=\"3\">",
"       Intervals for recommended screening strategies:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"3\">",
"       &bull; Annual screening with high-sensitivity fecal occult blood testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"3\">",
"       &bull; Sigmoidoscopy every 5 years, with high-sensitivity fecal occult blood testing every 3 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"3\">",
"       &bull; Screening colonoscopy every 10 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Balance of harms and benefits",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       The benefits of screening outweigh the potential harms for 50- to 75-year-olds.",
"      </td>",
"      <td colspan=\"2\">",
"       The likelihood that detection and early intervention will yield a mortality benefit declines after age 75 because of the long average time between adenoma development and cancer diagnosis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Implementation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"      <td colspan=\"3\">",
"       Focus on strategies that maximize the number of individuals who get screened.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Practice shared decision making; discussions with patients should incorporate information on test quality and availability.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Individuals with a personal history of cancer or adenomatous polyps are followed by a surveillance regimen, and screening guidelines are not applicable.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Relevant USPSTF recommendations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"3\">",
"       The USPSTF recommends against the use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer. This recommendation is available at www.preventiveservices.ahrq.gov.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents please go to www.preventiveservices.ahrq.gov.",
"    <br>",
"     <strong>",
"      Disclaimer:",
"     </strong>",
"     Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the US Department of Health and Human Services.",
"     <div class=\"footnotes\">",
"      * These recommendations do not apply to individuals with specific inherited syndromes (Lynch Syndrome or Familial Adenomatous Polyposis) or those with inflammatory bowel disease.",
"      <br>",
"       # FOBT testing requires three separate stool samples.",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"      Adapted from: US Preventive services task force, Screening for colorectal cancer: US preventive services task force recommendation statement, Annals of Internal Medicine 2008; 149:627.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_13005=[""].join("\n");
var outline_f12_44_13005=null;
var title_f12_44_13006="Obesity and NIDDM";
var content_f12_44_13006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increasing body weight increases risk of diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rates of impaired glucose tolerance and diagnosed and undiagnosed type 2 diabetes in the United States adult population according to increase in percent desirable weight from age 25 years to age at maximum adult weight (about 50 years).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Harris, MI, Diabetes Care 1989; 12:464.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_44_13006=[""].join("\n");
var outline_f12_44_13006=null;
var title_f12_44_13007="Contents: Labor and delivery";
var content_f12_44_13007=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Labor and delivery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Labor and delivery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Analgesia and anesthesia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/40/39562\">",
"           Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34248\">",
"           Airway management of pregnant women at delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/57/31639\">",
"           Intrapartum fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25977\">",
"           Neuraxial analgesia and anesthesia for labor and delivery: Drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/44/37574\">",
"           Neuraxial analgesia and anesthesia for labor and delivery: Options",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/44/38601\">",
"           Nonpharmacological approaches to management of labor pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/36/3657\">",
"           Obstetric anesthetic management of women with acquired or congenital heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/46/38633\">",
"           Pharmacologic management of pain during labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/4/10311\">",
"           Preparation for labor and childbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/31/40439\">",
"           Pudendal and paracervical block",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cesarean delivery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/2/39977\">",
"           Anesthesia for cesarean delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/62/44009\">",
"           Cesarean delivery of the obese woman",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/21/344\">",
"           Cesarean delivery on maternal request",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/60/21449\">",
"           Cesarean delivery: Postoperative issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/5/8282\">",
"           Cesarean delivery: Preoperative issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/21/14682\">",
"           Cesarean delivery: Technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/10/5290\">",
"           Choosing the route of delivery after cesarean birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11414\">",
"           Fetal extraction at cesarean delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37862\">",
"           Repeat cesarean delivery",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Delivery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/11/2232\">",
"           Antepartum fetal heart rate assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/42/13992\">",
"           Approach to episiotomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/29/25048\">",
"           Birth centers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11414\">",
"           Fetal extraction at cesarean delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41752\">",
"           Intrapartum management and outcome of shoulder dystocia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/57/20374\">",
"           Intrapartum management of the low birthweight vertex fetus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/21/33114\">",
"           Management of normal labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/21/5462\">",
"           Management of the fetus in occiput posterior position",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7858\">",
"           Management of the fetus with compound presentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26742\">",
"           Mechanism of normal labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13124\">",
"           Occiput transverse position",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/39/15994\">",
"           Operative vaginal delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/53/20312\">",
"           Planned home birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/1/5141\">",
"           Precipitous birth not occurring on a labor and delivery unit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42903\">",
"           Procedure for vacuum assisted operative vaginal delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/34/8743\">",
"           Puerperal uterine inversion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1930\">",
"           Reducing adverse obstetrical outcomes through safety sciences",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/22/3433\">",
"           Repair of episiotomy and perineal lacerations associated with childbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/1/16408\">",
"           Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fetal assessment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/11/2232\">",
"           Antepartum fetal heart rate assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1253\">",
"           Fetal acid-base physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/38/31337\">",
"           Fetal macrosomia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38311\">",
"           Management of intrapartum category I, II, and III fetal heart rate tracings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35702\">",
"           Umbilical cord blood acid-base analysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/24/35208\">",
"           Diagnosis and management of retained placenta after vaginal birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/37/15961\">",
"           Disseminated intravascular coagulation during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/11/22711\">",
"           Intrauterine balloon tamponade for control of postpartum hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/38/42600\">",
"           Overview of postpartum hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29367\">",
"           Peripartum hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection transmission",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/31/4602\">",
"           Epidemiology, transmission, and prevention of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18698\">",
"           Group B streptococcal infection in neonates and young infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/57/31639\">",
"           Intrapartum fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/19/26936\">",
"           Vertical transmission of hepatitis C virus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Labor",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/2/11306\">",
"           Abnormal labor: Protraction and arrest disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5252\">",
"           Amnioinfusion: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/12/43203\">",
"           Amnioinfusion: Technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/11/2232\">",
"           Antepartum fetal heart rate assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/29/25048\">",
"           Birth centers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/55/28535\">",
"           Cervical ripening and induction of labor in women with a prior cesarean delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/20/22855\">",
"           Continuous intrapartum support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38326\">",
"           Face and brow presentations in labor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/25/28053\">",
"           Insertion of intrauterine pressure catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/57/31639\">",
"           Intrapartum fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9189\">",
"           Latent phase of labor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/21/33114\">",
"           Management of normal labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/8/22662\">",
"           Management of the fetus in transverse lie",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7858\">",
"           Management of the fetus with compound presentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26742\">",
"           Mechanism of normal labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/49/43799\">",
"           Neuroprotective effects of in utero exposure to magnesium sulfate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13124\">",
"           Occiput transverse position",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/37/31322\">",
"           Principles of labor induction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1930\">",
"           Reducing adverse obstetrical outcomes through safety sciences",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/0/41993\">",
"           Techniques for ripening the unfavorable cervix prior to induction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/51/29494\">",
"           Umbilical cord prolapse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/42/41639\">",
"           Uterotonic drugs for management of the third stage of labor",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Maternal medical problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/29/2519\">",
"           Intrapartum and postpartum management of insulin and blood glucose",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13434\">",
"           Management of hypertension in pregnant and postpartum women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/19/20794\">",
"           Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/7/29818\">",
"           Pregnancy in women with congenital heart disease: General principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/21/35159\">",
"           Pregnancy in women with congenital heart disease: Specific lesions",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple gestation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/34/12842\">",
"           Triplet pregnancy: Mid and late pregnancy complications and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/11/5306\">",
"           Twin pregnancy: Labor and delivery",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-656E1BDED9-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f12_44_13007=[""].join("\n");
var outline_f12_44_13007=null;
